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Comprehensive in vitro modelling of inflammatory human skin conditions is an 
essential first step in the development and assessment of potential therapeutic 
approaches. Mouse models or monolayer keratinocyte cultures come with distinct 
limitations which might be complimented or overcome by the use of human-specific 
organotypic 3D culture models. 
Over the course of this thesis, an organotypic culture system, based on patient-
derived immortalised keratinocyte cell lines on a dermal equivalent collagen 1 gel, 
was established and used to recapitulate phenotypical features for two hereditary 
skin diseases, Harlequin ichthyosis and Tylosis with oesophageal cancer. Small 
molecular compounds, supplied via the medium, or RNA interference were used to 
modulate disease-specific changes in histology and marker expression of the skin 
equivalent. 
Since hyperproliferative skin conditions can be associated with an aberrant wound 
healing phenotype, the organotypic system was manipulated to obtain a basic in vitro 
wound healing model. This model displays typical features of re-epithelialisation over 
time (both normal and disease-specific) which can further be manipulated via shRNA-
mediated knockdown or the exogenous supply of compounds. 
In parallel, a non-disease model was used to assess the topical application of novel 
nanopolymeric drug delivery systems in regard to their ability to penetrate across the 
permeability barrier. Penetrance profiles for the organotypic model (in dependence 
of co-application with chemical enhancers) showed a similar pattern as for topical 
applications performed in parallel on explant skin. 
In conclusion, a highly adaptable human organotypic keratinocyte culture model was 
developed and used to recapitulate (and manipulate) skin disease phenotypes and 
epidermal wound healing in vitro, as well as perform first essential assessments of 
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1.1. Structure and Function of the Human Skin  
 
The skin is not just the largest organ in the human body but also its protection against 
external assaults of different biological, chemical and physical varieties as well as 
water loss from the inside (Figure 1) (Proksch et al. 2008). In order to sustain this 
function, it is comprised of an outer epidermal layer, a stratified assembly of 
keratinocytes in varying stages of differentiation, which is in turn structurally 
supported and supplied with nutrients by the underlying dermis, a mechanically 
strong and flexible matrix arrangement containing further neural, vascular, glandular 
as well as immune system components. Underneath epidermis and dermis, a 
subcutaneous connective and adipose tissue layer serves as additional thermal and 
mechanical insulation as well as attachment to the muscular tissue (Figure 2) 






Figure 1: Human skin barrier function 
The human skin in general and the epidermis in 
specific serve as barrier against diverse 
environmental assaults as well as protection 
against excessive trans-epidermal water loss and 
subsequently dehydration of the body. (Proksch 





Figure 2: Structure of the human skin 
Human skin is comprised of several distinct layers: epidermis, dermis and subcutis. The epidermis as 
the outermost layer is the major factor in the barrier function of the skin whereas the mostly collagen-
based dermis lends structural support by being tightly connected to the epidermis via the basement 
membrane. In addition, it anchors a variety of glands, hair follicles and contains blood vessels for 
nutrient supply. The subcutaneous adipose tissue serves as insulation, padding and attachment to the 





The dermis is a fibrous connective tissue component of the skin that lends tensile 
and elastic properties to the tissue while also retaining water and harbouring skin 
appendages (Jepps et al. 2013). Its two layers, the relatively thin papillary region and 
the underlying thick reticular region, are defined by different extracellular matrix 
compositions as well as cellular content and demarcated by the presence of a 
horizontal plane of capillaries, the subpapillary plexus. Intertwining with the 
epidermis through epidermal rete ridges and dermal papillae, the 100 – 200 µm thick 
papillary region is mostly comprised of a relatively loose network of thin collagen 1 
fibres surrounded by glycosaminoglycans (mostly hyaluronan) and proteoglycans. It 
contains most of the dermal cells which are predominantly fibroblasts and cells of 
the innate immune system (macrophages, mast cells, dermal dendrocytes) in 
Introduction 
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addition to tactile and thermosensitive nerve endings. In contrast, the reticular 
dermis is comprised of a tightly interwoven network of large-diameter collagen, 
elastic and reticular fibres, which is mainly responsible for the mechanical strength 
of the skin. It is also in this part where the majority of blood vessels, hair follicles, 







Being structurally supported and supplied with nutrients by the underlying, 
vascularised dermis, the epidermis is comprised of a layered assembly of 
keratinocytes undergoing terminal differentiation while migrating in an outwards 
direction (Figure 3) (Fuchs 1990; Simpson et al. 2011). The lowermost layer is referred 
Figure 3: Stratification and functional layering of the epidermis 
The epidermis is structured into several distinct layers (“strata”) of keratinocytes in progressing 
states of terminal differentiation, each layer being characterised by a defining set of functional 
features (morphology, intercellular contacts, protein and lipid synthesis). (Simpson et al. 2011) 
Introduction 
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to as the stratum basale. It is separated from the dermis by the collagen 4 and 
laminin-rich basal lamina on which it is tightly anchored by hemidesmosomes, 
comprised of integrins (Paulsson 1992; Margadant et al. 2010). Epidermal stem cells, 
thought to reside in the bulge region of hair follicles outer root sheaths as well as 
‘epidermal proliferative units’ in the basal layer of the interfollicular epidermis, 
provide a continuous supply of keratinocytes for tissue homeostasis and 
regeneration in case of wounding (Cotsarelis 2006; Strachan and Ghadially 2008; 
Blanpain and Fuchs 2009). From this basal layer of mitotically active cells asymmetric 
cell division, driven by a perpendicular orientation of the spindle apparatus, gives rise 
to suprabasal keratinocytes (Lechler and Fuchs 2005; Fuchs 2008). These cells cease 
their mitotic activity and commit to a terminal differentiation program when entering 
the stratum spinosum, due to the aforementioned asymmetrical, perpendicular cell 
division or, in early stages of development, delamination. (Williams et al. 2014). In 
addition, the Notch-dependent downregulation of the transcription factor p63 is 
indicated to be an essential regulator in the switch from proliferation to 
differentiation (Nguyen et al. 2006; Senoo et al. 2007; Estrach et al. 2008). With the 
commitment to stratification and the concomitant onset of differentiation several 
distinct changes occur in the keratinocytes of the stratum spinosum. For one, the 
cytoskeletal composition changes, with the basal cytokeratins 5 (CK5) and 14 (CK14) 
being replaced by cytokeratin 1 (CK1) and 10 (CK10) (Eichner et al. 1986).  
Furthermore, desmosomes exhibit a change in individual subunits accompanied by 
an increase in size and number, facilitating stronger intercellular contacts and 
affecting cell morphology from a cubic to a more elongated shape (Mcmillan et al. 
2003; Brandner et al. 2010).  
A distinct feature of the next layer of the epidermis, the stratum granulosum, is the 
increased production of keratohyalin granules and lamellar bodies. Keratohyalin 
granules contain predominantly profillagrin and loricrin, two important structural 
components for the formation of the cornified envelope in subsequent layers (Watt 
1983). Lamellar bodies serve as storage / transport compartment for a multitude of 
lipids and enzymes/proteases, the secretion of which in the upper stratum 
granulosum is of equal importance for the establishment of a functional barrier in 
the next layer, the stratum corneum (Feingold 2012). Contributing to the barrier 
Introduction 
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function of the skin in the upper epidermis, tight junctions are formed in the apical 
parts of the stratum granulosum (Kirschner et al. 2010).  
The outermost layer of the epidermis, the stratum corneum, is comprised of by now 
terminally differentiated corneocytes. Undergoing apoptosis, they expel their 
intracellular contents, in addition to the exocytosis of keratohyalin and lamellar 
granules at the transition from stratum granulosum to corneum, and change into a 
tightly packed, flattened morphology. This change is facilitated through the collapse 
and aggregation of intermediated filaments (mostly CK1 and CK10), whereby this 
process is supposed to be promoted by the proteolytically cleaved filaggrin (Dale and 
Presland 1997). Further crosslinking of the filament bundles with additional structure 
proteins loricrin and involucrin as well as fully matured corneodesmosomes into a 
tightly knit submembraneous matrix by transglutaminase 1 (TGM1) gives mechanical 
support to the cornified envelope (Candi et al. 2005). Lipid lamellae are being formed 
by cholesterol, ceramides and free fatty acids, which surround the protein 
components of the cornified envelope, and are key to the epidermal permeability 
barrier function (Feingold and Elias 2014). The incorporation of antimicrobial 
peptides, such as beta-defensins and cathelicidins, provide a microbial barrier (Elias 
and Choi 2005). In the course of skin homeostasis dead corneocytes are then 
continuously shed of the skin through desquamation; a process that is facilitated by 
the degradation of corneodesmosomal components, namely desmoglein 1 and 
corneodesmosin, by serine proteases (Caubet et al. 2004). 
In addition to keratinocytes, which make up 95% of epidermal cells, various other cell 
types can be found throughout the epidermis (Figure 4) (Burns et al. 2008). 
Melanocytes are specialised cells in the stratum basale, producing pigment-
containing melanosome and transporting them via dendrites to the surrounding 
basal and suprabasal keratinocytes. Once there, the melanosomes localise around 
the nucleus and protect its DNA from UV radiation-induced mutagenesis (Agar and 
Young 2005; Nissan et al. 2011). Also located in the basal layer of the epidermis are 
the so-called Merkel cells. Associated with somatosensory afferent nerve fibres these 
receptor cells have recently been proved to be essential for light-touch sensation 
(Halata et al. 2003; Maricich et al. 2009). As epidermal part of the immune system, 
Langerhans cells on the other hand are predominantly found in the stratum 
Introduction 
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spinosum. Classified as professional antigen-presenting cells, these dendritic cells are 
a crucial component in the adaptive immune response to skin-resident pathogens 
(Langerhans 1868; Clausen and Kel 2010). 
 
 
While the epidermis is dependent on dermal blood vessels for the diffusion-based 
supply of nutrients, it has been shown that epidermal oxygen supply happens almost 
exclusively through the uptake of external atmospheric oxygen, creating a reverse 
gradient to the basally supplied nutrients (Stücker et al. 2002). Another important 
gradient in the epidermis is based on the concentration of extracellular calcium ions 
(Menon et al. 1992). Calcium is an important regulator of keratinocyte differentiation 
and cell-cell adhesion (Elsholz et al. 2014); it is therefore no surprise that calcium 
concentrations can be found to increase in suprabasal layers, with the highest 
concentration in the stratum granulosum . Upwards of this layer, the relative dryness 
of the stratum corneum results in a distinct drop in extracellular calcium, which 
further regulates the exocytosis of lamellar and keratohyalin granules (Lee et al. 
1992). In addition, calcium was found to be an important regulator of protein 
synthesis in the epidermis and essential for the activity of transglutaminases (Hitomi 
2005). 
Figure 4: Non-keratinocyte cells of the 
epidermis 
Apart from keratinocytes the epidermis is 
comprised of several other cell types. In the 
basal layer are melanocytes, that protect 
surrounding cells from phototoxicity, as well 
as somatosensory Merkel cells. Antigen-
presenting Langerhans cells can be found 





1.2. Hereditary Skin Disorders 
 
The World Health Organisation provides a comprehensive listing for diseases of the 
skin and subcutaneous tissue in Chapter 12 of the ICD-10. The classified types of 
disorders are hereby divided into eight different classes, dependent on localisation 
and cause of the individual disease (Table 1). 
 
Table 1: Diseases of the skin and subcutaneous tissue according to ICD-10 
 
 CLASS EXAMPLES 
L00 – L08 
Infections of the skin and 
subcutaneous tissue 
Cutaneous abscess (L02), 
Cellulitis (L03) 
L10 – L14 Bullous disorders 
Pemphigus (L10), Acquired 
epidermolysis bullosa (L12.3) 
L20 – L30 Dermatitis and eczema 
Atopic dermatitis (L20),  
Exfoliative dermatitis (L26) 
L40 – L45 Papulosquamous disorders 
Psoriasis vulgaris (L40.0), Lichen 
planus (L43) 
L50 – L54 Urticaria and erythema 
Allergic urticaria (L50.0), Bullous 
erythema mulitforme (L51.1)  
L55 – L59 
Radiation-related disorders of 
the skin and subcutaneous tissue 
Sunburn (L55), Radiodermatitis 
(L58) 
L60 – L75 Disorders of skin appendages 
Hypertrichosis (L68), Acne 
vulgaris (L70.0) 
L80 – L99 
Other disorders of the skin and 
subcutaneous tissue 
Acquired ichthyosis (L85.0), 
Keloid scarring (L91.0) 
  
 
While Chapter 12 only lists acquired disorders, hereditary skin defects can be found 
in ICD-10 Chapter 17: Congenital malformations, deformations and chromosomal 








Table 2: Congenital malformations, deformations and chromosomal abnormalities according to ICD-
10 (excerpt for the skin-specific sections Q80-82) 
 
 CLASS EXAMPLES 
Q80 Congenital ichthyosis 
Ichthyosis vulgaris (Q80.0), 
Harlequin ichthyosis (Q80.4) 
Q81 Epidermolysis bullosa 
Epidermolysis bullosa simplex 
(Q81.0) 






Since the functional homeostasis of the epidermis and especially stratification 
towards a viable permeability barrier is dependent on a tightly regulated network of 
protein expression across all stages of keratinocyte differentiation, disease 
phenotypes such as the ones listed in the ICD-10 can often be traced back to originate 
in loss- or gain-of-function mutations in single genes encoding essential epidermal 
proteins. Simpson et al. provided a comprehensive list of mutations and associated 
disorders, a selection of which is presented here (Table 3) (Simpson et al. 2011).  
Congenital disorders (of the skin as well as other organs) have the distinct advantage 
of being very suitable for disease modelling. Animal models such as mouse or zebra 
fish can be modified via mutagenesis or more recently CRISPR/Cas9 methodology to 
recapitulate human monogenic disease phenotypes (Rossant and McKerlie 2001; 
Lieschke and Currie 2007; Platt et al. 2014). Further on, human cell-based in vitro 
models can be generated, even for more complex polygenic disorders, by using 
patient-derived and tissue-specific cell lines or reprogrammed induced pluripotent 
stem cells (Tiscornia et al. 2011; Soldner and Jaenisch 2012; Robin et al. 2015). These 
human cell models would then further allow for the genomic manipulation (e.g. 
functional repair) of disease-causing mutations (Cong et al. 2013; Schwank et al. 




Table 3: Mutations in epidermal proteins and associated diseases 
(excerpt from a table originally published by Simpson et al. 2011) 
 
PROTEIN DISEASE REFERENCE 
Gap junctions   
Cx26 Keratitis ichthyosis deafness syndrome (Richard et al. 2002) 
Cx30 Hidrotic ectodermal dysplasia (Lamartine et al. 2000) 
Keratin filaments   
K16, K17 Pachyonychia congenita (McLean et al. 1995) 
K5, K14 Epidermolysis bullosa simplex (Bonifas et al. 1991) 
Desmosomes   
DSG3 Pemphigus vulgaris (Amagai et al. 1991) 
DP, DSG1 Striate palmoplantar keratoderma (Norgett et al. 2000) 
Hemidesmosomes   
Laminin 5 Junctional epidermolysis bullosa (Pulkkinen et al. 1994) 
Stratum corneum   
ABCA12 Harlequin ichthyosis (Kelsell et al. 2005) 




1.2.1. Harlequin Ichthyosis 
 
Harlequin Ichthyosis (HI; OMIM #242500; ICD-10 Q80.4) is a rare form of congenital 
ichthyosis, a family of genetic skin disorders being generally characterised by dry, 
scaly, thickened skin and varying widely in severity from mild types such as ichthyosis 
vulgaris to the far more severe Harlequin Ichthyosis, which can be fatal shortly after 
birth. It features a severely thickened skin with ‘armour-like’ scales being separated 
by deep fissures, which leaves the newly born with a high risk of dehydration, 
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impaired thermoregulation and infection (Figure 5). Preliminary data suggests that 
early-on treatment with oral retinoids greatly increases the chance of survival, with 
older children changing to a phenotype resembling severe nonbullous congenital 
ichthyosiform erythroderma (Rajpopat et al. 2011). 
 
 
The molecular basis for HI is a recessive loss-of-function mutation in the ABCA12 
gene (Akiyama 2005; Kelsell et al. 2005). ABCA12 encodes for a transmembranous 
lipid transporter found localised in lamellar granules of the stratum granulosum 
where it is proposed to be involved into the packaging of glycosylceramides into the 
lamellar bodies. Those glycosylceramides are then, together with other lipids and 
enzymes, transported to the apical plasma membrane of granular keratinocytes, 
released into the intercellular space and consequently contribute to the proper 
formation and processing of the cornified envelope in the stratum corneum (Ishida-
Yamamoto et al. 2004). Due to the loss of transport function and impaired loading of 
lipids, lamellar bodies are found to be abnormally shaped, reduced in size and 
number in affected epidermis. The resulting lipid imbalance in the stratum corneum 
(Figure 6a) is thought to affect the tightly regulated differentiation program in the 
epidermis, leading to a premature terminal differentiation phenotype (Figure 6b) 
(Thomas et al. 2009). Furthermore, with proteases such as kallikrein 5 and 
cathepsin D not being properly transported to the stratum corneum (Figure 6b), 
formation of the permeability barrier and later desquamation of apical corneocytes 
Figure 5: Clinical presentation of HI at birth 
New-borns display a severely thickened and deeply fissured skin that results in a heightened risk 
of dehydration and infection and subsequently death, if left untreated. (Kelsell et al. 2005) 
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are severely impaired, leading to the distinct phenotype of HI (Figure 6c) (Ishida-






Figure 6: Phenotypical features of HI 
Epidermis of HI patients displays a striking lipid imbalance, with in this case green-fluorescent non-
polar lipids being completely absent from suprabasal layers. (Thomas et al. 2009) (A). Staining of 
protein markers in HI skin reveals an increased expression of differentiation markers (involucrin, 
cytokeratin 2e) in lower layers of the epidermis and complete absence of specific proteases such as 
kallikrein 5 and cathepsin D  (Thomas et al. 2009) (B). As a result of dysregulated differentiation and 






Tylosis with oesophageal cancer (TOC; OMIM #148500, ICD-10 Q82.8) is a dominantly 
inherited syndrome of focal palmoplantar keratoderma. Affected individuals typically 
display thickened skin on palm and soles, oral leukokeratosis (Figure 7) and have a 
heightened susceptibility for oesophageal squamous cell carcinoma (up to 95% by 
the age of 65) (Ellis et al. 1994).  
 
The underlying cause for this syndrome was discovered to be an autosomal-
dominant mutation in the RHBDF2 gene encoding iRHOM2 (Blaydon et al. 2012). 
iRHOM2 belongs to a family of inactive rhomboid serine proteases and is involved in 
the epidermal growth factor receptor (EGFR)-signalling pathway via one of its 
substrates, the sheddase ADAM17. Hereby, the gain-of-function mutation in iRhom2 
leads to a heightened rate of maturation of ADAM17, accompanied by a 
translocation from the trans-Golgi to the plasma membrane, and consequently an 
increased shedding of epidermal growth factor receptor (EGFR) ligands and other 
cytokines (Figure 8) (Brooke et al. 2014). The resulting upregulation in EGF-mediated 
signalling is presumed to be the cause for the hyperproliferative keratoderma 
phenotype and the susceptibility for oesophageal cancer (Blaydon et al. 2012) and 
was furthermore indicated to lead to an increased permeability and microbial barrier 
function in the epidermis (Brooke et al. 2014). In addition, ADAM17 is describe to be 
Figure 7: Clinical presentation of TOC 
Patients with TOC typically display palmoplantar keratoderma (A) and oral leukokeratosis (B). 
(Blaydon et al. 2012) 
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widely involved in processes associated with inflammation and tissue regeneration 
(Arribas and Esselens 2009; Scheller et al. 2011), for example via its substrates 
Interleukin 6 and 8 which have been shown to exhibit positive effects on epidermal 
wound healing (McKay and Leigh 1991; Gallucci et al. 2000; Rennekampff et al. 2000). 
Subsequently, TOC keratinocyte have recently been described to possess features of 
“constitutive wound healing” (Brooke et al. 2014; Ellis et al. 2015). 
Figure 8: Phenotypical features of TOC keratinocytes 
TOC keratinocytes display an increased plasma membrane localisation of the sheddase ADAM17 
(TACE) (A) which is accompanied by an upregulated iRHOM2-driven maturation, visible by a stronger 
presence of the free pro-domain of the enzyme (B). As a result TOC keratinocytes secret a higher 
amount of EGF-family growth factors such as Amphiregulin, TGFD and HB-EGF (C) as well as certain 
cytokines, e.g. Interleukin 6 and Interleukin 8 (D). The underlying steps of ADAM17 maturation and 
activity are tied to several subcellular compartments (E). (modified from Adrain and Freeman 2012; 
Brooke et al. 2014) 
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1.2.3. Pachyonychia Congenita 
 
Pachyonychia congenita (PC; OMIM 167200; ICD-10 Q84.5) is autosomal 
dominantly inherited form of palmoplantar keratoderma (Leachman et al. 2005), 
presenting itself in a clinical phenotype that involves painful keratoderma of the 
palms and soles, nail deformities, epidermal cysts and oral leukokeratosis (Figure 9) 
(Smith et al. 1993). The underlying molecular cause was found to be missense 
mutations in genes for several intermediate filaments, whereas mutations in Keratin 
6a and 16 (CK16) are responsible for Type 1 PC and Keratin 6b and 17 lead to Type 2 
PC (Bowden et al. 1995; McLean et al. 1995). Further details about the specific 
disease-causing mechanism are so far unknown but almost all PC-related mutations 
occur in the conserved 1A helical domain for each of the affected keratins (Terrinoni 
et al. 2001). These helix boundary motifs have also previously been described as 
mutational hotspot for most of the characterised keratin disorders (Fuchs and 
Cleveland 1998; Irvine and Mclean 1999). Possible treatment options for PC include 
the post-transcriptional downregulation of Keratin 6a through mTOR inhibitors such 




Figure 9: Clinical presentation of Pachyonychia congenita 
Typical symptoms of PC are thickened and/or dystrophic finger and toe nails (a-c), painful plantar 
keratoderma including calluses and underlying blisters (d-e), epidermal cysts (f) and oral 
leukokeratosis (g). (Smith et al. 1993) 
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1.3. Cutaneous Wound Healing 
 
1.3.1. Physiological Process of Cutaneous Wound Healing 
 
The repair of acute cutaneous wounds is a well-orchestrated process involving a 
variety of cellular components from the epidermis, dermis, immune system and 
vasculature (Singer and Clark 1999). This process is classically divided in three distinct 
but overlapping phases over time: inflammatory phase, proliferative phase and 
remodelling phase (Figure 10) (Gurtner et al. 2008). 
 
 
Figure 10: Stages of cutaneous wound repair 
The classical description of cutaneous wound healing is based on three sequential but overlapping 
phases. The first phase, lasting up to three days from injury, is the inflammatory phase and involves 
an initial haemostasis followed by immune-mediated clearance of the wound (a). Subsequently, 
during the up to two weeks long proliferative phase, newly formed granulation tissue forms the basis 
for re-epithelialisation from the wound edge (b). The remodelling phase can last up to a year and ends 
with mature, structurally strong scar tissue replacing the granulation tissue and lending support for 
the fully functional, reformed epidermis (c). (modified from Gurtner et al. 2008) 
 
The inflammatory phase happens in the immediate aftermath of an injury and 
involves the initial stabilisation and clearance of the wound area (Martin and 
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Leibovich 2005). As a first step in this haemostasis is established through the 
formation of a plug by extravasated platelets and fibrin, whereby this haemostatic 
plug also serves as a matrix for the migration of infiltrating immune cells. Neutrophils 
are recruited into the wound by platelet degranulation and activation of the 
complement system via bacteria and clean the wound via proteolytic breakdown and 
phagocytosis of debris as well as antibacterial activity. In conclusion to this action 
and subsequent apoptosis they are either extruded with the eschar or themselves 
phagocytised by macrophages. The macrophages are thought to be crucial in setting 
up the next stage of the healing process by secreting a multitude of cytokines and 
growth factors essential for the initiation and propagation of new epithelial tissue 
formation and neovascularisation after the initial few days of inflammation (Figure 
11), though recent studies suggest that redundancies in the inflammatory response 
can mitigate missing (cellular) factors (Martin and Leibovich 2005). Among the newly 
formed structures is the granulation tissue, being made up of sprouting capillaries, 
remaining macrophages and recruited fibroblasts. Replacing the fibrin clot, it is 
mainly composed of fibronectin, hyaluronan and in increasing parts collagen 3 in 
order to provide a scaffold for migration of endothelial and epithelial cells. Even 
during the inflammatory phase keratinocytes from the wound edge, or alternatively 
from potential appendageal remainders inside the dermis, start to migrate into the 
wound, degrading hemidesmosomal contacts with the basement membrane and 
upregulating the expression of several integrins and matrix-metalloproteases to 
allow for the lateral migration from the injured dermis and unto the newly formed 
granulation tissue (Larjava et al. 1993; Pilcher et al. 1997). This mechanism of 
migration and proliferation and maturation, leading in the end to a fully functional 
epidermis, is hereby thought to be driven by growth factors derived from the 
macrophages and fibroblasts inside the underlying tissue (Figure 11), in addition to 
the loss of contact inhibition and certain wound-specific chemicals such as nitric 
oxide (Witte and Barbul 2002; Zegers et al. 2003). Myofibroblasts, which are 
contractile cells derived from triggered differentiation of dermal fibroblasts inside 
the granulation tissue, help with this re-epithelialisation process by contracting the 
wound and bringing the edges closer together (Werner et al. 2007). During the last 
phase, which normally starts around two weeks after injury and can last up to a year, 
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the provisional, collagen 3-containing granulation tissue is gradually remodelled into 
a collagen 1-rich, crosslinked and aligned tissue by the incorporated fibroblasts, 
potentially triggered in this by epidermally secreted TGF-b (Clark et al. 1995). In the 
end, the majority of remaining endothelial cell, macrophages and fibroblast undergo 
apoptosis or exit the wound, leaving a most acellular, structurally strong scar tissue 
underneath the newly formed epidermis (Desmoulière et al. 1995).  
 
  
Figure 11: Cellular crosstalk during cutaneous wound healing 
Proper progression through the stages of cutaneous wound repair and subsequent re-
establishment of a functional epidermis is dependent on a well-coordinated interplay of cellular 
components from the immune system (neutrophils and macrophages), endothelial cells, dermal 
fibroblasts and re-epithelialising keratinocytes. Most of this interaction is regulated by the timed 
secretion of growth factors leading to recruitment and/or functional activation of receipting 
cells. (modified from Singer and Clark 1999) 
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1.3.2. Aberrant Wound Healing and Therapeutic Approaches 
 
Cutaneous wound healing is a complex process and can therefore be impaired by 
various factors. These can be either local, for example ischemia or excessive dryness 
of the wound, or especially systemic factors, such as age, nutrition, diabetes or 
inflammation (Guo and Dipietro 2010). In contrast, hypertrophic scarring and keloid 
formation are prominent examples of excessive healing, either due to external or 
genetic factors, and consequently characterised by unusually upregulated 
vascularisation and cell proliferation as well as subsequent aberrant deposition of 
extracellular matrix (Robles and Berg 2007; van der Veer et al. 2009). The 
understanding of underlying mechanisms allows for the possibility of therapeutic 
intervention, potentially through external stimulation of angiogenesis in diabetic 
wounds or the inhibition of TGF-b in hypertrophic scar formation (Figure 12) 
(Ferguson et al. 2004; Galiano et al. 2004). 
Another important to consider in terms of cutaneous wound healing is the difference 
between tissue repair and regeneration: while repair refers to the physiological 
adaption and re-establishment of continuity after a tissue injury, regeneration means 
a complete morphological and functional restoration of the tissue (Orgill and Blanco 
2009). While the former is the case with normal wound healing, the latter is under 
ongoing investigation, with the idea being that the right combination of stem cell-
based tissue engineering approaches and instructive scaffolds could results in the 
fully functional reconstruction of dermal appendages such as sweat glands (Figure 
12) (Lutolf and Hubbell 2005; Huang et al. 2012). These considerations become 
especially important in the context of bioengineered wound covers and skin 
substitutes, which are crucial in the treatment of large-area (burn) wounds and will 
be mentioned again later on in Chapter 1.5.1 (Matoušková and Mestak 2014; 





Figure 12: Artificially improved cutaneous regeneration 
While normal (and especially aberrant) wound healing results in acellular dermal scar tissue, 
advances in growth factor-based treatment in combination with tissue engineering approaches 
might result in the regeneration of fully functional skin, including normal dermis and appendages.  
(Gurtner et al. 2008) 
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1.4. Epidermal and Transdermal Drug Delivery 
 
1.4.1. Caveats of Percutaneous Transport 
 
Hereditary skin conditions offer the possibility of disease phenotype alleviation via 
systemic application of drugs, for example retinoids in case of Harlequin ichthyosis 
or mTOR inhibitors for the treatment of Pachyonychia congenita (Warren and 
Khanderia 1989; Hickerson et al. 2009; Rajpopat et al. 2011; Nguyen and Zuniga 
2013). Oral administration of these drugs is known though to lead to, partially severe, 
systemic side effects (Gollnick 1996; Salmon 2015). Local administration, which in 
case of skin disorders means external application of a topical formulation, is 
therefore a preferable administration route and consequently the focus of ongoing 
development (Falke et al. 2015; Feely et al. 2015; van de Kerkhof 2015). In addition, 
the transdermal administration of systemically active drugs has several advantages 
over oral or injection-based routes, for example in terms of pharmacodynamics and 
users acceptance (Prausnitz and Langer 2008).  
When it comes to the epidermal and transdermal delivery of substances across the 
upper layers of the epidermis several possible pathways are considered to be feasible 
(Figure 13). Transappendageal transport relies on the presence of hair shafts and 
glandular ducts in order to reach lower epidermal layers and is therefore considered 
a preferential pathway but nonetheless insignificant for overall transport since 
follicles and glands make up only 0.1% of the skin surface (Blank et al. 1967; Schaefer 
and Lademann 2001). In contrast, interfollicular transport (trans- and predominantly 
intercellular) is far more likely but severely hindered by the by the native barrier 
function of the epidermis where penetration across stratum corneum and upper 
stratum granulosum is highly limited and dependent on a multitude of factors, like 
molecular weight and partition coefficient (Pouillot et al. 2008; Proksch et al. 2008; 




Figure 13: Epidermal permeation pathways of topically applied substances 
Topically applied substances are thought to be transported across the epidermis in a variety of 
possible ways. Intercellular transport happens in between the corneo- and keratinocytes, across the 
lipid lamellae (a), whereas transcellular transport relies on the temporary internalisation and 
excretion of the permeating substances (c). Transappendageal transport uses hair follicles or glands 
to reach lower epidermal layers (b) and microlesions across upper layers of the epidermis would also 
allow for a similar permeation (d). (Prausnitz et al. 2004) 
 
Building on the consideration of more complex biochemical / biophysical properties 
of applied substances and formulations, a considerably more complex picture 
regarding the restricting factors of (trans-)epidermal delivery emerges (Figure 14). 
These models not only take into account size-dependent exclusion, partition and 
diffusion of particles after release from a formulation and across the different layers 
of the epidermis (all of which can be described as mathematical models) but also 
more broader, physiological aspects such as binding and metabolisation in addition 
to vascular and immune clearance as soon as substances reach the dermis (Jepps et 






Figure 14: Factors influencing transdermal transport of topically applied substances 
After the release of a drug from the applied formulation a variety of factors influence its permeation 
into and across the skin. Size- and concentration-dependent diffusion (described by Fick’s first and 
second law) as well as the partition, determined by the hydro- and lipophilicity of the substance, are 
important biophysical factors in the initial transport across the upper layers of the epidermis. These 
get complemented by more complex interactions with the tissue, such as binding to biological 
structure, internalisation and metabolisation through cells. Once the substance reaches the dermal 
layer, clearance via the immune system and vasculature play an important role in the withdrawal of 







1.4.2. Facilitation of Percutaneous Drug Delivery 
 
In parallel to working on more refined methods of understanding and modelling the 
barrier function of the skin, a variety of approaches and techniques have been 
developed to facilitate percutaneous drug delivery. These different approaches are 
hereby based on physical as well as (nano-) chemical applications (Trommer and 
Neubert 2006; Prausnitz and Langer 2008; Alexander et al. 2012; Wong 2014; 
Schmieder et al. 2015). 
 
1.4.3. Physical Methods of Enhancing Percutaneous Delivery 
   
Examples for the physical enhancement of transdermal delivery of drugs are 
iontophoresis, electroporation, sonophoresis, microneedles and jet injection 
(Raphael et al. 2015). 
Iontophoresis is based on the application of a small electrical current across the 
treated skin region (maximum of 0.5mA/cm2) which, instead of disrupting the skin 
structure, provides an adaptable electrical driving force. This force leads to the 
electrophoretic movement of small, charged drugs whereas uncharged compounds 
can also exhibit a limited degree of movement through electroosmotic water flow 
(Kalia et al. 2004; Dhote et al. 2012). 
Electroporation also works with the applications of an electrical current but instead 
of a continuous small current repeated high-voltage pulses (50-1500V for 
microseconds to milliseconds per interval) are used. As a consequence, in addition 
to a short-lived electrophoretic field during each pulse interval longer-lasting lipid 
bilayer disruptions and electropores are generated across the upper layers of the 
epidermis, which allow for an enhanced diffusion of low and high molecular weight 
substances (Charoo et al. 2010; Ita 2016). 
Sonophoresis includes the application of ultrasound (20 kHz to 16 MHz depending on 
application) to the skin which is thought to increase drug permeation mostly through 
thermal effects as well as acoustic cavitation, leading to the disruption of lipid 
structures via oscillating small gaseous bubbles (Azagury et al. 2014; Park et al. 2014). 
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Microneedles are usually comprised of an array of microscopic needles that, when 
applied as a patch on the skin, penetrate between 100 and 300 µm into the epidermis 
and superficial dermis. This creates temporary micro-fissures along which topically 
applied substances can diffuse in the tissue. Furthermore, microneedles can be 
coated with a drug and thereby used to directly delivery it or alternatively 
biodegradable microneedles can encapsulate a substance and subsequently act as a 
reservoir, slowly releasing it through degradation of the actual needle (Prausnitz 
2004; Gonzalez-Gonzalez et al. 2010).  
Jet injection involves the painless application of high pressure and velocity in order 
to force a liquid or powder across the epidermis and is therefore a popular 
alternative to traditional needle-based, transdermal injections (Hogan et al. 2015).   
Naturally, over time combinatorial approaches emerged as well in the attempt to 
further the efficiency of existing methods, for example through the combination of 
microneedles and ultrasound (Chen et al. 2010) or electroporation and iontophoresis 
(Tokumoto et al. 2006). 
 
 
1.4.4. Chemical Methods of Enhancing Percutaneous Delivery 
 
Chemical penetration enhancers are varied in nature and possible mechanism of 
action (Figure 15). Aiming primarily on the disruption of intercellular lipid bilayers in 
the stratum corneum, several categories of chemicals have been used to-date 
(Williams and Barry 2012; Lane 2013). Several properties for the ideal penetration 
enhancer have hereby been defined early on and include, among others, non-toxicity 
and –irritancy, rapid and quickly reversible effect on permeation and the absence of 
pharmacological activity (Barry 1983). A few examples of investigated types of 
chemicals for enhanced cutaneous penetration (though far from a comprehensive 
listing) are alcohols, azones, fatty acids, surfactants and sulphoxides. Alcohols such 
as ethanol, isopropyl and benzyl alcohol (BA) are commonly used in aqueous 
solutions as solvents for drugs, increasing their solubility (and consequently the 
drug’s partitioning in the lipophilic phases) and further destabilising the lipid bilayers 
of the stratum corneum through lipid extraction and lipid fluidisation (Berner et al. 
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1989; Nanayakkara et al. 2005; Engelbrecht et al. 2012). Azone was the first 
specifically designed penetration enhancer (Stoughton and McClure 1983). Strongly 
lipophilic and with a relatively large polar head group, this non-irritant, non-toxic 
compound is thought to intercalate into lipid bilayers and increase their fluidity. Fatty 
acids and especially unsaturated, cis-configured varieties such as oleic acids have 
been found to be viable penetration enhancers as well, presumably though 
incorporation and subsequent perturbation of the lipid lamellae (Jiang and Zhou 
2003; Van Zyl et al. 2016). Surfactants (preferentially non-ionic for increased 
biosafety) are another commonly used class of penetration enhancers, being able to 
solubilise lipophilic active compounds as well as lipids of the stratum corneum and 
also form micelles for the phase separation of lipid bilayers (Sarpotdar and Zatz 1986; 
Palma et al. 2006).  Dimethylsulphoxide (DSMO) has been widely published and used 
as especially potent solvent and is in consequence also applicable as penetration 
enhancer. The enhancing effect is hereby attributed to several mechanisms: 
interaction with lipids and generation of solvent-filled spaces inside the bilayers, 
extraction of lipids and also changes in keratin conformation due to water 
displacement (Rammler 1967; Anigbogu et al. 1995). One problem that arises in 
parallel to the potency of DMSO is its well-known range of side effects from skin 




Figure 15: Categorisation and possible action of penetration enhancers at intercellular lipids 
Chemical penetration enhancers can be classified in several categories (A) and interact with and 
consequently disrupt the lipid lamellae of the stratum corneum in variety of ways, dependent on 
the chemical properties of the specific enhancer category (B). (modified from Trommer and 






1.4.5. Nanochemical Methods of Enhancing Percutaneous Delivery 
 
With the advance of nanotechnology the idea of using chemical adjuvants to 
transport small molecular compounds across the epidermis has been further 
developed into a variety of different nanomaterial-based approaches for (trans-) 
dermal delivery (Prow et al. 2011; Delouise 2012; Antonio et al. 2014; Arif et al. 
2015). Nanomaterials, which depending on the definition should not exceed 100-200 
nm in dimension, are of special interest for emerging technologies due to their 
different physicochemical properties in comparison with macroscale materials of the 
same composition, which is mostly based on the drastically increased surface-to-
volume ratio (Figure 16) (Nel et al. 2006; Misra et al. 2008).  
 
 
Figure 16: Comparative size of various nanoparticles 
Nanoparticles vary in size but should not exceed 200nm, which puts them in the same dimension as 
phage viruses and enables them to readily interact with considerably larger cell structures. (Van Rijt 
et al. 2014) 
 
Subsequently, over the years different types of specifically designed nanomaterials, 
varying hugely in composition and properties, have been applied in a variety of fields 
(Figure 17). Metal core particles, based for example on oxidized titan or silver 
molecules, are increasingly used in consumer products such as sunscreens or 
deodorants (Contado 2015). Medical diagnostic applications make use of superior in 
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vivo contrast imaging that can be achieved with tumour-specific fluorescent 
quantum dots or superparamagnetic iron particles (Padmanabhan et al. 2016). 
Furthermore, several therapeutic approaches are based on the application of 
nanoparticles, for example by utilising them as antimicrobial agents (Rudramurthy et 
al. 2016), in physical tumour therapy (Zhang et al. 2016) or as drug carrier system 
(Cho et al. 2008), whereby in those last two cases the ability to functionalise 
nanoparticles and make them specifically bind to certain molecular targets is of 
special importance (Liu et al. 2014; Adebowale et al. 2015). 
 
Figure 17: Selection of different nanoparticle types 
Different types of nanoparticles are varied in their chemical composition, ranging from lipid complexes 
over polymeric structures to metal and carbon complexes, and subsequently in their physicochemical 
properties. (Van Rijt et al. 2014) 
 
 
As mentioned above, nanoparticles as drug delivery vehicles are also of particular 
interest in the field of dermatology and different nanomaterials have been utilised in 
the past in order to optimise dermal and transdermal delivery of compounds. In this 
context, the ability of different nanoparticle types to effectively cross the epidermal 
permeability barrier is an on-going matter of debate, with potential permeation 
being seemingly very dependent on size, composition and application of the specific 
nanoparticle (Baroli 2010; Lademann et al. 2013; Watkinson et al. 2013; Larese Filon 
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et al. 2015). Flexible, lipophilic nanopolymers such as micelles have been well 
demonstrated to permeate along the intercellular spaces of the stratum corneum 
(Cevc 2004; Sinico and Fadda 2009). Solid nanoparticles, especially when 
approaching a size of 40nm and above, on the other hand appear to be generally 
hindered in their penetration and rely on the co-administration of chemical 
penetration enhancers (Smijs and Bouwstra 2010; Campbell et al. 2012). 
Alternatively, most nanoparticles seem to show significant advantages in terms of 
transappendageal transport, being able to deeply penetrate along hair follicles and 
form drug releasing reservoirs (Lademann et al. 2007; Fang et al. 2014). 
Subsequently, even though solid nanoparticles do not necessarily facilitate 
epidermal permeation by themselves they might still be of interest for drug delivery, 
especially when taking into account other properties specific to certain types of 
nanomaterials that allow for a targeted or triggered release of a drug, for example in 
response to changes in pH or temperature (Cheng et al. 2013; Karimi et al. 2016).  
One interesting option would hereby the application of thermoresponsive nanogels 
(Molina et al. 2014; Bergueiro and Calderõn 2015). Poly(N-isopropylacrylamide) 
(PolyNIPAm) forms a thermosensitive hydrogel when chemically crosslinked, 
undergoing a reversible phase transition at 32°C; above this temperature the nanogel 
changes into a dehydrated state, shrinking to approximately 10% of its initial volume 
and expelling its content (Yan and Tsujii 2005; Cuggino et al. 2011). Since this 
conformational change happens at a temperature close to body temperature, it has 
already been investigated for its potential in controlled transdermal drug delivery 
(Singka et al. 2010; Witting et al. 2015). 
The potentially harmful effects of naturally occurring and man-made 
nanoparticulates, for example as part of industrial exhaust, have been under 
investigation for some time and the rise of nanomaterial-based applications further 
presses the need for comprehensive studies of cytotoxicity and systemic effects for 
biomedically or cosmetically applied nanoparticles (Dowling et al. 2004; Buzea et al. 
2007; Kennedy 2014). In this regard, suitable in vitro models are of special 
importance for initial safety assessments but also to gain further insight into 
mechanisms of action for nanoparticles once applied to the tissue (Tsuji et al. 2006; 
Sayes et al. 2007).   
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1.5. In vitro-generated Skin Equivalents 
 
The generation of in vitro skin equivalents can be broadly divided into two potential 
applications: the creation of skin substitutes for therapeutic purposes and cutaneous 
models for in vitro test assays as well as discovery science (Figure 18) (Groeber et al. 
2011).  
 
Figure 18: In vivo and in vitro application of skin equivalents 
In vitro tissue-engineered skin equivalents can be generated by the combination of human-derived 
cells and suitable biomimetic scaffolds and subsequently used either for in vivo application as 
therapeutic skin substitute or for in vitro test models. (Groeber et al. 2011) 
 
 
1.5.1. Therapeutic Application of Tissue-engineered Skin Substitutes 
 
Skin substitutes are a promising treatment option for large-scale wound (for example 
from extensive burns), where autologous skin grafts are no longer viable due to 
limited availability (Shahrokhi et al. 2014). While momentary skin covers are 
predominantly acellular matrices (either of biological or synthetic origin) that allow 
for a facilitated migration of cells into the wound area and subsequently improved 
re-epithelialisation, it has been shown that the incorporation of (autologous) cells of 
different origins can greatly improve the outcome (Nicholas et al. 2016). 
Introduction 
 36 
Furthermore, recent advances in tissue engineering lead to the potential addition of 
functional appendages such as sweat glands into the newly generated skin tissue 
(Huang et al. 2010). An important aspect in the development of these advanced skin 
substitutes are the high requirements in regard to quality control, safety assessments 
and commercialisation, that have to be taken into account when aiming for a viable 
therapeutic product and create additional, specific demands for the generation of 
this kind of skin equivalents (Bannasch et al. 2010).  
 
1.5.2. Use of Human Skin Equivalents as in vitro Models 
 
In regard to the second potential field of application, human skin equivalents become 
an increasingly essential tool in industrial research in order to accommodate 
progressively thorough regulatory requirements for the hazard assessment of novel 
substances (e.g. REACH Regulation [EC] 1907/2006). The use of animal models in 
pharmaceutical and especially cosmetic industry was a long-standing standard 
(Phillips et al. 1972) but has been drastically scaled down recently due to decreasing 
social acceptance and legislative support; with the 3Rs-principle finding itself 
increasingly included in regulatory policies across the EU (e.g. EU Directive 
2010/63/EU; 7th Amendment EU Cosmetics Directive 76/78/EEC) and United States 
(Schechtman 2002; Becker et al. 2006). Furthermore, enzymes responsible for drug-
metabolism can differ widely in between species; rendering the transfer of 
cytotoxicity results from animal to human difficult (Martignoni et al. 2006). Thus, 
there is a necessity for the development of suitable, human-specific in vitro test 
systems (Astashkina et al. 2012; Vellonen et al. 2014). Monolayer cell cultures are 
hereby a good first approximation but lack the three-dimensional cell-cell and cell-
matrix interactions of the native tissue as well as proper metabolisation 
characteristics, therefore necessitating more complex, in vivo-like models (Figure 19) 
(Sun et al. 2006; Götz et al. 2012a). In case of assessing epidermal interactions of 
novel compounds and carriers, using skin explant cultures, for example obtained as 
surplus material from plastic surgeries or as patient samples, delivers a most in vivo-
like setting but is severely limited in regard to availability and reproducibility due to 
biological variation in between samples; reconstructed skin equivalents have 
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therefore to be considered as an alternative (Ponec 2002). Recreating skin biology in 
a sufficient but scalable manner, those models could then be used as extension for 
initial assessments of basic parameters in monolayer cultures (Poumay and Coquette 
2007; Pappinen et al. 2012; Rimann and Graf-Hausner 2012). By applying cultured 
keratinocytes in a standardised setting, batch-to-batch variety can be kept 
comparatively low and the possibility of up-scaling is only limited by cell culture 
facilities and the available budget (Lotte et al. 2002). Correspondingly, various 
commercially available skin equivalents have been made available over the last two 
decades and used to for the assessment of skin corrosion and irritancy of novel 
products, adhering hereby to guidelines established by the OECD (OECD TG 431 / 
439) regarding for example the viability, morphology and reproducibility of a specific 
test system. Existing products can hereby be divided into two categories: epidermal 
models, which consist of epidermal keratinocytes on a synthetic membrane (e.g. 
Episkin¥ by L’Oréal or EpiDerm¥ by MatTek Corporation), and full-thickness models, 
Figure 19: Complexity and relevance of various in vitro models 
In vitro skin models show a general correlation in between their complexity and relevance for test 
systems, ranging from simple monolayer to 3D culture (both epidermal and full-thickness) and explant 
cultures as most in vivo-like option. Multi-organ chips, which combine several reconstructed tissues 




which include an additional cellularised dermal component (e.g. EpiDermFT¥ by 
MatTek Corporation or the Phenion£ FT Model by Henkel AG). In general, it can 
hereby be said that the full-thickness models are closer to native skin in several 
biological parameters, for example lipid composition and barrier function, than the 
epidermal models but conversely require more effort in regard to standardisation 
and reliable readout due to the increased complexity (Mathes et al. 2014). This has 
to be taken into consideration when expanding the use of a model to address more 
complex questions such as permeation of topically applied substances for intended 
transdermal delivery or localisation and effect inside the epidermis (Gabbanini et al. 
2009; Ackermann et al. 2010). For academic research full-thickness models are also 
the more preferential option since the increased complexity is essential in the study 
of physiological and aberrant skin biology. 
 
1.5.3. Matrix and Cellular Components of Skin Equivalents 
 
The first concern when it comes to three-dimensional cell culture in general is the 
choice of the right scaffolding. While epidermal models can be achieved by culturing 
keratinocytes on simple synthetic membranes in airlift, more complex models (and 
most commercially available ones) have an additional collagen coating for better cell 
adhesion (Frankart et al. 2012; Pendaries et al. 2014). In contrast, full-thickness 
models require a dermal component as well and provide thereby the chance for more 
variation in the choice of material. De-epidermalised dermis (DED), mostly acquired 
from cadaver skin, is a commonly used support for the reconstruction of full skin 
(Tjabringa et al. 2008; Bogaard et al. 2013). Close in morphology to actual skin once 
supplied with keratinocytes, it comes with mostly the same advantages and 
disadvantages as skin explants, namely availability but especially biological 
variability. Similar de-cellularised scaffolds can also be generated from animal tissue 
such as porcine intestines (Jannasch et al. 2015; Lindberg and Badylak 2015). 
Reducing the dermal support structure to simplified extracellular matrix protein gels, 
collagen 1 as major constituent of the dermis being hereby a preferred candidate, 
makes for a more reproducible and scalable model and has therefore become a 
widely used method (Mildner et al. 2010; Eckl et al. 2011; Gschwandtner et al. 2013). 
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Instead of using single protein gels, different proteins can furthermore be combined 
to mimic a biologically more relevant composition, for example by applying collagens 
1;3 and 5 in conjunction with elastin (Reijnders et al. 2015). Conversely and in order 
to counteract biological variability even further the protein matrix can be (partially) 
substituted by synthetic polymers like polycarbonate, polystyrene or 
polycaprolactone (Dai et al. 2004; Sun et al. 2005; Poumay and Coquette 2007). 
Another approach works entirely without an artificially created scaffold, instead 
relying on high-density fibroblast sheets to self-assembly an extracellular matrix to 
seed the keratinocytes on (Cvetkovska et al. 2009; Jean et al. 2009). 
Regarding the choice of keratinocytes for the epidermal portion of the organotypic 
culture, several alternative types of cell supply have to be considered. While the 
majority of the literature describes the successful generation of in vitro skin models 
based on primary keratinocytes and fibroblasts (Mildner et al. 2006; Bogaard et al. 
2013; Alnasif et al. 2014) and all commercially available models are based them as 
well, using immortalised cell lines has certain advantages over the use of primary 
cells (Reijnders et al. 2015). By applying a continuously self-renewing supply of cells, 
experiments can be conducted over a long time frame without risking variability in 
results due to aging or having to replace cell supplies (Schoop et al. 1999; Kolditz et 
al. 2014; Skazik et al. 2014). Furthermore, in case of rare genetic disorders 
transforming a small pool of primary cells, yielded from a singular skin sample, is the 
only possibility to achieve a sufficient supply of cells for in vitro studies without 
having to rely on artificial, transient or permanent knockdown models (Blaydon et al. 
2012, 2013) which becomes even more prevalent when dealing polygenic disorders. 
On the other hand, the quality of immortalised skin equivalents does appear to be 
hugely dependent on the specific setup and especially the source of the used cell 
line. While for example successful models, including proliferation and differentiation 
similar to primary keratinocytes, based on human telomerase reverse transcriptase 
(hTERT) and spontaneously immortalised keratinocytes have been previously 
published (Allen-Hoffmann et al. 2000; Dickson et al. 2000; van Drongelen et al. 
2014), other groups described insufficient barrier properties and lack of typical 
metabolic redox activity in HaCaT-based organotypics (Boelsma et al. 1999; Götz et 
al. 2012b) or premalignant, hyperproliferative phenotypes with human papilloma 
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virus (HPV)-immortalised keratinocyte organotypic cultures (Blanton et al. 1991; 
Delvenne et al. 1995, 2001). In regard to organotypic disease modelling, if patient-
derived cells are not available, stable knockdown models for disease-specific genes 
using either primary or immortalised cells, are a viable option and have been 
described extensively in the literature (Mildner et al. 2010; Eckl et al. 2011; Pendaries 
et al. 2014; Skazik et al. 2014). Furthermore, novel TALEN- and CRISPR/Cas9-based 
approaches make it possible to introduce sequence-specific mutations into cultured 
cells and by that reproduce disease-related gene defects (Gaj et al. 2013; Wei et al. 
2013). Another intriguing alternative is made possible by the rather recent advance 
of somatic cell reprogramming, with skin equivalents being based on keratinocytes 
derived from patient-specific, induced-pluripotent stem cells (Itoh et al. 2013; 
Petrova et al. 2014). Having established an (disease-based) organotypic culture 
model, it can then be used to further elucidate disease mechanisms and/or assess 
the effect of potentially therapeutic compounds in a more skin-like, three-
dimensional setting (Bogaard et al. 2013; Alnasif et al. 2014; Eckl et al. 2014). 
In addition to keratinocytes and fibroblasts, as minimal essential components of a 
dermal/epidermal model, other cell types and constructs can be introduced to the 
skin equivalent. Different kinds of melanocytes can be added in order to investigate 
pigmentation or melanoma formation (Duval et al. 2012; Hill et al. 2015), the addition 
of Langerhans cell or macrophages can introduce an immunological component to 
the model (Linde et al. 2012; Ouwehand et al. 2012) and endothelial cells, 
alternatively re-differentiated from adult stem cells first, allow for capillary formation 
in the dermal portion of the skin equivalent (Black et al. 1998; Auxenfans et al. 2012). 
Of similar importance for the potential application in therapeutic skin equivalents is 
the possibility to transplant or de novo-reconstruct appendages like hair follicles and 
sweat glands, which is also interesting for in vitro permeation models due to the 
preferential transappendageal transport route of some topically applied substances 





1.5.4. Skin Equivalents in Disease, Wound and Infection Models 
 
With the right choice of cells (either patient-derived, genetically manipulated or 
biochemically triggered) skin equivalents can be used for the complex in vitro-
modelling of disease phenotypes. Consequently, over the course of the last decade 
numerous disease models have been published. Some examples are hereby based 
on keratinocyte-specific disorders, such as psoriasis (Tjabringa et al. 2008; Krajewska 
et al. 2011), chloracne (Forrester et al. 2014), atopic dermatitis (Bogaard et al. 2013), 
recessive congenital ichthyosis (Eckl et al. 2011) and exfoliative ichthyosis (Blaydon 
et al. 2011). Other models concentrate on dermal fibroblasts instead, in order to 
investigate for example mechanisms of hypertrophic scarring (van den Broek et al. 
2012, 2014). Combinatorial approaches can involve disease-related changes in both 
keratinocytes and fibroblasts, which would for example cause basement membrane 
abnormalities in models for dystrophic epidermolysis bullosa (Itoh et al. 2011, 2013). 
Furthermore, additional cell types can be included into the model to create specific 
phenotypes, like the addition of activated T cells for eczematous dermatitis 
(Engelhart et al. 2005) or aberrant melanocytes for the generation of an organotypic 
melanoma model (Hill et al. 2015). 
In addition to disease models, skin equivalents can also be used to model and 
characterise simple wound healing processes.  Several models have hereby been 
used to investigate basic keratinocyte (and fibroblast) behaviour during re-
epithelialisation in response to burn or cold wounds, superficial incisions or full-
thickness punch wounds (El Ghalbzouri et al. 2004; Breetveld et al. 2006; Safferling 
et al. 2013).  
Regarding the use of functional skin equivalents for the in vitro investigation of 
infections, models have been developed including all major types of pathogens: 
bacteria such as Staphylococcus aureus (Popov et al. 2014), fungi like Candida 
albicans (Schaller et al. 2002), a variety of relevant viruses (Andrei et al. 2010) and 
also worm larvae (Jannasch et al. 2015). Bacterial infection models have recently 
been further combined with thermal wounding of the skin equivalent in order to 
have a more specific look at the interaction of S. aureus with the wound milieu and 
the potential of therapeutic intervention (Haisma et al. 2014).  
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1.6. Aims of the Thesis 
 
Combining various aspects of in vitro skin modelling, the overall aim of this thesis is 
the establishment of an adaptable protocol for the generation of organotypic skin 
disease model and its application in the characterisation of hyperproliferative 
disease phenotypes, the modulation of said phenotypes through potential 
therapeutic approaches and the parallel use of the functional organotypic for the 
assessment of topically applied nanopolymeric drug delivery. The thesis has 
therefore the following aims (Figure 20): 
 
9 Establishment of an organotypic culture model for HPV16-immortalised 
keratinocyte cell lines (normal phenotype and patient-derived) 
 
9 Application of the organotypic culture protocol for the generation of phenotypic 
models for Harlequin ichthyosis, Tylosis and Pachyonychia congenita 
 
9 Modulation of modelled disease phenotypes through the application of 
appropriate, potentially therapeutic compounds 
 
9 Establishment of an organotypic epidermal wound model and its combination 
with the TOC disease model 
 
9 Use of the normal phenotype model for the assessment of topically applied 
nanopolymers in regard to (assisted) permeation in addition to general 





Figure 20: Principle and aims of the thesis 
Patient-derived and normal phenotype keratinocytes are immortalised, expanded and subsequently 
used to establish a 3D organotypic model. The model is then characterised both for the normal 
phenotype (in comparison to explant skin) and disease phenotypes (in comparison to the normal 
phenotype). In conclusion to this, compounds are used to modulate the specific disease phenotypes, 
an organotypic wound model is established and combined with certain disease models and the normal 
phenotype model is used to assess nanopolymer interaction and permeation (again in comparison to 
explant skin).
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2. Materials and Methods 
 
2.1. Tissue- and Cell Culture 
 
2.1.1. Maintenance Culture of Immortalised and Primary Keratinocytes 
 
Patient-derived and normal control keratinocytes were initially isolated from skin 
biopsies using established protocols (Blaydon et al. 2012). In short, freshly explanted 
skin biopsies (2mm diameter) were cleaned from excess fat tissue, washed in 
phosphate buffered saline (PBS) and transferred to 2.5 mg/ml Dispase 1 (Roche) for 
overnight incubation at 4°C. The next day, dermis and epidermis were pulled apart 
via tweezers and the epidermis treated separately from here on. The tissue was 
washed several times in Versene solution containing 0.2 g/l EDTA in PBS (Thermo 
Fisher Scientific) and then chopped with a scalpel before being transferred to a 
trypsin-EDTA solution (0.5 g/l trypsin and 0.2 g/l EDTA in PBS; Sigma-Aldrich) for 2h 
at 37°C. After further dissociation of the tissue pieces through up- and down suction 
in increasingly smaller volume pipettes, the now cloudy cell suspension was pelleted 
(0.2g for 5 minutes), resuspended (in differentiation medium without the addition of 
Ham’s F12; see Table 5) and added unto a semi-confluent layer of pre-seeded NIH-
3T3 immortalised and growth-arrested feeder fibroblasts. After an initial culture 
period of 48 hours (at 37°C and 10% CO2 in a humidified incubator), half of the 
medium was changed every other day and additional feeder cells added if necessary. 
The cells were passaged when keratinocyte colonies reached about 50% confluency. 
For this, feeder fibroblasts were washed off through a 5 minutes’ incubation period 
in Versene and then keratinocytes detached via 5 to 10 minutes in trypsin-EDTA. 
After pelleting and resuspending, the cells were then either seeded unto a new batch 
of feeder fibroblasts or alternatively cultured on their own in serum-free 
maintenance medium (Table 5).  
Established keratinocyte cultures, as well as previously immortalised cell lines (Table 
4), were kept in maintenance medium (at 37°C and 10% CO2); medium was changed 
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every other day and the cells passaged when reaching 80% confluency. In order to 
passage the keratinocytes, cells were washed once in PBS and incubated in trypsin-
EDTA for 5 to 10 minutes. When the cells were detached, the suspension was 
neutralised via adding equal volume Trypsin Neutralizer Solution (Thermo Fisher 
Scientific) and then pelleted (0.2g for 5 minutes) and resuspended in maintenance 
medium before seeded into a new culture flask. If necessary, cells were counted 
before the pelleting using a NucleoCounter NC-100 (Chemometec). 
Assessment of viability in (treated) monolayer cells was determined via an Alamar 
Blue Viability assay (Thermo Fisher Scientific) according to the manufacturer’s 
instructions. Cells were incubated with the assay solution for 3-4 hours at 37°C to 
assure good conversion of the dye and for the final readout the red fluorescence 
(585 nm) per well was determined with an automated plate reader.  
 
Table 4: Keratinocyte cell lines 
Control or disease-specific cell lines were immortalised from primary keratinocyte cultures either 
spontaneously (Boukamp et al. 1988) or through introduction of genes for hTERT (Lee et al. 2004) or 
HPV16 E6/7 (Storey et al. 1988). 
 
 Immortalisation Source 
HaCaT spontaneous 





HI skin from patient with Harlequin ichthyosis  with recessive mutation for ABCA12 (p.Glu2264X) 
TOC skin from patient with Tylosis  with dominant mutation for iRHOM2 (p.Ile186Thr) 
PC skin from patient with Pachyonychia congenita  with dominant mutation for CK16 (p.Leu128Glu) 
 
 
2.1.2. Maintenance Culture of Primary Dermal Fibroblasts 
 
In order to isolate and culture dermal fibroblast from healthy skin biopsies first steps 
were done in parallel to the isolation of epidermal keratinocytes (see above). 
Subsequently to the Dispase 1 digestion and separation of the dermis and epidermis, 
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the dermis was washed in PBS and cut with a scalpel in 1 cm2 pieces before evenly 
distributed in a fresh culture plate. The plate was kept at 37°C for 1 hour in order to 
allow for the tissue pieces to dry and adhere unto the plastic surface. Fibroblast 
medium (Table 5) was slowly added from the side of the dish and the tissue kept at 
37°C (10% CO2) for at least 48 hours without movement. Medium was changed 
carefully in accordance with phenol red-based discoloration and the tissue pieces 
observed for eventual outgrowing of fibroblast cells. After obtaining sizeable 
fibroblast colonies through outgrowth, cells were then passaged through 
trypsinisation and reseeding into fresh culture dishes (see above for details).  
 
 
Table 5: Media compositions 
Ingredient Supplier Product no. Final concentration 
Fibroblast medium 
DMEM Sigma-Aldrich D5671  
FCS life technologies 16000044 10% 
L-Glutamine Sigma-Aldrich G7513 2 mM 
Pen/Strep Sigma-Aldrich P0781 100 units/ml (Pen) 100 µg/ml (Strep) 
Maintenance medium (0.06 mM Ca2+) 
Epilife life technologies M-EPI-500CA  
HKGS life technologies S-0015 1% 
Pen/Strep Sigma-Aldrich P0781 100 units/ml (Pen) 100 µg/ml (Strep) 
Differentiation medium (1.5 mM Ca2+) 
DMEM Sigma-Aldrich D5671  
Ham’s F12 Sigma-Aldrich 51651C 25% 
FCS life technologies 16000044 10% 
L-Glutamine Sigma-Aldrich G7513 2 mM 
Pen/Strep Sigma-Aldrich P0781 100 units/ml (Pen) 100 µg/ml (Strep) 
RM+ in-house formulation (see Table 6) 
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Table 6: Composition of RM+ 
Ingredient Supplier Product no. Final 
concentration 
Choleratoxin Sigma-Aldrich C8052 1x10-10 M 
EGF Serotec EGF-1 10 ng/ml 
Hydrocortisone Sigma-Aldrich H4881 0.4 µg/ml 
Insulin Sigma-Aldrich I5500 5 µg/ml 
Transferrin Sigma-Aldrich T2252 5 µg/ml 
L-Thyronin Sigma-Aldrich T6397 2x10-11 M 
 
 
Established primary fibroblast cultures were kept in fibroblast medium at 37°C and 
10% CO2 in humidified incubators. Medium was changed every other day and cells 
were passaged when reaching 100% confluency. 
 
 
2.1.3. shRNA-mediated Protein Knockdown in Keratinocytes 
 
Selected keratinocyte cell lines were treated with small hairpin-RNA (shRNA) 
lentiviral particles in order to silence iRHOM2 protein expression. Transduction-
ready particle mixtures (Santa-Cruz) contained hereby three individual constructs 
encoding a target-specific 19-25 nucleotide sequence (plus hairpin) and puromycin 
resistance cassette. For the transduction, cells were grown in 6well plates to 60% 
confluency before being treated with 5 µg/ml polybrene (in maintenance medium) 
for 20 minutes at 37°C and then incubated with the lentiviral particles (either specific 
for iRHOM2 or scrambled shRNA negative control) overnight at 37°C. The following 
day transduced cells were positively selected by using medium containing 2µg/ml 
puromycin for another three days before being switched back to normal 
maintenance medium. The degree of iRHOM2 knockdown was confirmed by using 
Western Blotting (Chapter 2.7).  
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2.1.4. Generation of Organotypic Keratinocyte Cultures – Alvetex Model 
 
A first protocol for the generation of organotypic skin models was based on the 
application of Alvetex polystyrene scaffolds (Reinnervate). The highly porous, 200µm 
thick scaffolds (Figure 21 a) were hereby first rehydrated in 70% ethanol and washed 
twice in fibroblast medium before being placed in a 6well via the attached hanging 
culture insert (Figure 21 b). Primary dermal fibroblasts were seeded directly into the 
rehydrated scaffold (1 million cells in 100µl fibroblast medium) and incubated for 1 
hour at 37°C before being cultured for up to three weeks under submerged 
conditions (fibroblast medium from underneath and inside the culture insert) at 37°C 
(10% CO2) with medium changes every two to three days. Following this first culture 
period all the medium was removed and immortalised keratinocytes seeded directly 
on top of the cellularised scaffold (1 million cells in 100µl differentiation medium) or 
alternatively on a freshly prepared uncellularised scaffold. After incubating the cells 
on the scaffold for 1 hour at 37°C  the complete scaffolds were submerged in 
differentiation medium and cultured like this for 2 days before being put in airlift 
culture condition (differentiation medium only from underneath the culture insert, 
Figure 21 c). The organotypics were cultured for up to an additional 3 weeks in airlift 
(at 37°C and 10% CO2, with medium changes every other day) before being harvested 
and processed for imaging. 
 
Figure 21: Preparation of Alvetex-based organotypics 
The Alvetex culture system consists of a highly porous, 200µm thick polystyrene scaffold (a; image 
provided by Reinnervate) that is incorporated into a hanging insert for mid-air positioning in 6well 
culture plates (b). For the essential airlift culture conditions medium levels in the 6well are adjusted 
to only reach the bottom of the culture insert, leaving the interior scaffold dry and air-exposed (c).  
(a) (b) (c) 
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2.1.5. Generation of Organotypic Keratinocyte Cultures – Collagen Model 
 
The protocol for the generation of collagen-based organotypics was based on 
published procedures (Mildner et al. 2006) and optimised for the use with in-house 
keratinocyte cell lines (Figure 22). As a first step, a 4 mg/ml collagen 1 solution was 
set up on ice by mixing a high-concentration (ranging from 8 to 9 mg/ml depending 
on batch) rat tail collagen 1 solution in acetic acid (VWR) with an according volume 
of cold fibroblast medium. The solution was then further neutralised with 0.1M 
sodium hydroxide, using the phenol red of the fibroblast medium as indicator. 
Primary human fibroblasts were resuspended in the neutralised collagen solution at 
a concentration of 250,000 cell per ml and the mixture pipetted into hanging culture 
inserts (Millicell 0.4µm polyethylene terephthalate (PET) 12well inserts, Millipore) 
with 350 µl per inserts. The inserts were then kept at 37°C for 30 minutes to allow 
for the collagen-fibroblast gels to completely polymerise. Polymerised gels were 
cultured submerged in fibroblast medium and cultured for 24 hours at 37 °C and 10% 
CO2. The next day, medium was aspirated and sterile plastic cloning rings (9.5mm 
inner diameter, Sigma-Aldrich) placed on top of the gels in order to account for the 
partial contraction of the gel and reseal the inner part for the following keratinocyte 
application. Keratinocytes were resuspended in differentiation medium (Table 5) and 
pipetted unto the resealed gels (100,000 cells per gel). The gels were kept in 
submerged conditions for another 24 hours, using the differentiation medium, to 
allow for the keratinocytes to settle unto the gel. After this last incubation time, the 
cloning rings were removed, all the medium aspirated and only replaced underneath 
the insert in order to create airlift culture conditions. From this point the 
organotypics were cultured in airlift for up to two weeks (in a humidified incubator 
with 37 °C and 10% CO2) with medium changes every other day.  For selected 
experiments, organotypics were treated with additional compounds (Table 7) by 
adding them to the normal differentiation medium and refreshing them every other 
day (adding DMSO to control organotypics as appropriate). 
Unless specifically stated otherwise, this protocol was used by default for the 
generation of all organotypics. 
 





Table 7: Compounds for the addition to organotypic and monolayer cultures 
 
Compound Description Concentration Supplier 
GW 0742 small-molecular PPARE/G agonist 10 µM Sigma-Aldrich 
TO 901317 small-molecular LXR agonist 8 µM Sigma-Aldrich 
Cetuximab therapeutic antibody against EGFR 1 µg/ml Merck 





Figure 22: Preparation of collagen-based organotypics 
As a first step in the preparation of collagen-based organotypics a fibroblast containing collagen 1 
gel is cast into a hanging insert and initially kept in submerged conditions (a; shown here with 
medium only on top of the collagen gel inside the insert). A plastic cloning ring is used to ‘reseal’ the 
organotypic before the application of keratinocytes on top of the gel (b). The next day the cloning 
ring is removed and the freshly prepared organotypic (c) put into airlift conditions for up to two 
weeks, during which its appearance distinctly changes to a flattened, dried out form (d).   
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2.1.6. Generation of Organotypic Wound Models 
 
For the first step in the generation of in vitro wound models, collagen 1 gels were 
cast in 6well hanging culture inserts (Millipore) (Figure 23 a). Gels were prepared as 
described above, with the optional omission of fibroblast or addition of 30 ng/ml EGF 
(Serotec). After culturing the fresh collagen gels for two days under submerged 
conditions, fibroblast medium was aspirated and the gels used as wound scaffold. 
For this, two weeks-old, fully differentiated organotypics were cut out of their culture 
inserts (but kept on the underlying PET membranes) and subjected to full-thickness 
punches through epidermal and dermal portion as well as the membrane, using a 
sterile 2mm biopsy punch (Stiefel). The punched organotypics were then transferred 
unto the wound scaffold collagen gels and the whole setup cultured in airlift 
conditions for an additional time period of up to five days, allowing the epidermal 
keratinocytes to migrate / proliferate along the scaffold collagen gel into the wound 
area (Figure 23 b).  After the completed culture period, the wound organotypics were 





Figure 23: Preparation of an organotypic wound model 
Collagen 1 gels were cast into 6well culture inserts and pre-cultured as wound scaffolds (a). Fully 
differentiated organotypics were then punched and transferred unto the wound scaffold to allow 
for wound healing processes to take place (b). 
(a) (b) 
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2.2. Preparation and Application of Fluorescent Nanopolymers 
 
PolyNIPAm-based nanopolymers (intended for the encapsulation and temperature-
dependent release of drug compounds) were synthesised and chemically 
characterised by Dr Dolca Fabregat-Montfort (School for Biological and Chemical 
Science, Queen Mary University London) (Figure 24).  The crosslinking of NIPAm via 
MBA and incorporation of fluorescent probes resulted hereby in globular polymers 
with an average diameter of 10 nm (Figure 25 a). Different surface charges for the 
nanopolymers was further achieved through the addition of either acrylic acid 
(negative surface charge) or N-(2-aminoethyl)acrylamide hydrochloride (positive 
surface charge). For one subset of experiments Flufenamic acid (FFA) was added to 
the nanopolymers in order to test for a triggered release of the model drug. 
The nanopolymers were obtained in freeze-dried form (stored in the dark an at RT) 
and reconstituted for application purpose by solubilising them in maintenance 
medium (for application on monolayer cells) or water (for topical application on skin 
or organotypics) at varying concentrations (ranging from 0.1 mg/ml to 10 mg/ml). To 
assure a homogenous single-polymer solution, the reconstituted polymers were 
sonicated (10 seconds at 3 Watt) and filtrated (0.4µm pore size) directly before use. 
The fluorescently labelled nanopolymers were applied on monolayer keratinocytes 
in 96well format for viability assessment and in 12well format on cover slips for 
imaging (OEx= 395 nm / OEx= 530 nm; Figure 25 b) . 
Figure 24: Drug release from thermo-responsive nanopolymers 
The encapsulated drug gets expelled from the nanopolymer as consequence from the volume decrease 
that take place above a certain temperature threshold (around 32 qC for the applied PolyNIPAm-based 
polymers). Figure provided by Dr Dolca Fabregat-Montfort (SBCS, QMUL). 
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(a) 
(b) 
Figure 25: Composition of fluorescently labelled nanopolymers 
Fluorescent nanopolymers were synthesised by crosslinking NIPAM monomers with MBA and the 
covalent linkage of fluorescent monomers (a). For imaging purposes, the nanopolymers displayed 
an excitation peak at 395nm, resulting in green fluorescence at around 530nm (b). Data provided by 
Dr Dolca Fabregat-Montfort (SBCS, QMUL). 
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2.3. Using Explant Skin and Organotypics for Topical Particle Application 
 
For the topical application of nanopolymer solutions normal skin was obtained as 
surplus material from plastic surgeries, transported in saline solution and processed 
under sterile conditions no later than 6 hours after surgery. Whole skin was 
separated from subcutaneous fat tissue and divided into 4cm2 pieces (Figure 26a). 
These pieces were either placed in a PBS-containing 6well plate for direct application 
or flash frozen on dry ice and stored at -80°C for later experiments. Sterile metal rings 
were used to create a reservoir for the applied solution. In addition to firmly pressing 
them unto the tissue the bottom edge was also coated with high-vacuum silicon 
grease (Dow Corning) in order to stick the components together and create a 
biologically inert and hydrophobic seal against leakage of the applied solution over 
time (Figure 26b). Organotypics were prepared in a similar fashion: after two-weeks 
culture, 4m plastic cloning rings were pressed into the organotypic with silicon grease 
acting as adhesive sealant (Figure 26c).  
Figure 26: Topical application of polymer solutions on explant skin and organotypics 
Fresh explant skin, received from plastic surgery, was cleaned from subcutaneous fat (a), divided into 
4cm2 pieces and placed in a 6well plate with PBS. A metal ring (with silicon grease applied to the 
bottom edge) was then pressed unto it in order to form a reservoir for the topically applied solution 
(b). Similarly, fully differentiated organotypics were kept in their culture inserts and a small-diameter 
plastic ring (again with silicon grease applied to the bottom edge) placed on top to allow for the 
topical application of polymer solutions (c). 
(b) (c) 
(a) 
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The fluorescently labelled nanopolymers were prepared as described above and 
reconstituted for this application’s purpose by solubilising them in an aqueous 
solution, containing 2% DMSO or BA for selected samples at 1 mg/ml. Polymer 
solutions were kept on the samples for up to 48 hours at 37°C and humidified 
conditions in a warm room before being discarded and the tissue samples being 
washed in PBS and processed for cryo sections. As a general control for the barrier 
function of skin or organotypic samples a highly fluorescent 1mM solution of Lucifer 
Yellow (LY, Sigma-Aldrich) in PBS was used for parallel topical application.      
 
 
2.4. Tissue Processing and Sectioning 
 
2.4.1. Preparation of Cryo Sections 
 
Treated skin and organotypic samples were washed in PBS and then submerged in 
OCT embedding medium (VWR) inside plastic embedding moulds. Sample-containing 
moulds were then placed directly on dry ice and kept until completely frozen through 
before being stored at -80°C. A cryotom (Bright OTF5000) was used to prepare 5µm 
thick full-diameter cross sections of the embedded samples, which were placed on 




2.4.2. Preparation of Paraffin Sections 
 
For paraffin embedding, skin and organotypic samples were first washed in PBS 
before being fixated in 4% paraformaldehyde (PFA) for 2 hours at room temperature 
(RT). Samples were then transferred into 70% ethanol and kept until further 
processing (up to 4h). Overnight processing of the samples was performed in a VIPTM 
5 Vacuum Infiltration Processor (Tissue-Tek) and involved a series of dehydration 
steps (Table 8). The following morning, the fixed and dehydrated tissue was taken 
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from the 60°C paraffin bath and embedded in paraffin blocks via quick freezing. The 
sample blocks were stored at RT and later on cooled down to 4°C for sectioning. 5µm 
thick sections were transferred from the microtome (Leica RM2235) unto surface-
treated microscopy slides via a 37°C water bath and kept at RT until further usage. 
 
Table 8: Steps for automated tissue processing 
Step Solution Temperature Time 
1 70% Ethanol RT 1 hour 
2 70% Ethanol RT 1 hour 
3 80% Ethanol RT 1 hour 
4 95% Ethanol RT 1 hour 
5 100% Ethanol RT 1 hour 
6 100% Ethanol RT 1 hour 
7 100% Ethanol RT 1 hour 
8 100% Ethanol RT 1 hour 
9 Xylene RT 1 hour 
10 Xylene RT 1 hour 
11 Paraffin 60°C 1 hour 
12 Paraffin 60°C 1 hour 
13 Paraffin 60°C 1 hour 
14 Paraffin 60°C until embedding 
 
 
2.5. Staining Techniques 
 
2.5.1. Histological Staining (Haematoxylin & Eosin) 
 
For haematoxylin & eosin (H&E) staining of paraffin sections, the sections were first 
de-paraffinised and rehydrated by transferring them through a series of two times 
xylene, 100% ethanol, 90% ethanol, 70% ethanol and de-ionised water (3 minutes for 
each step). From the de-ionised water, the sections were then transferred to a 
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solution of Gill’s haematoxylin (Sigma-Aldrich) for 5 minutes before being blued in 
running tap water for 10 minutes. After the blueing the sections were quickly dipped 
in de-ionised water and then submerged in eosin Y (Sigma-Aldrich) for 2min. 
Subsequently, the sections underwent a dehydration series (same steps as before, 
but in reverse and 1 minute each) before being air dried and mounted in xylene-
containing Entellan mounting medium (Millipore). 
 
In the case that cryo sections had to be used instead of paraffin sections, they were 
first brought to room temperature, washed once with PBS in order to wash of the 
OCT embedding medium and then fixated with 4% PFA for 30min at RT. The sections 
were then washed in de-ionised water and transferred to haematoxylin. From there 
on the protocol was identical to the one for paraffin sections. 
 
 
2.5.2. Immunocytochemistry (ICC) 
 
In preparation of the eventual staining, monolayer cells were cultured on sterile glass 
cover slips (VWR) in 12well culture plates. After culturing, and potential treatment, 
cells on cover slips were first washed once in PBS and then fixated with 4% PFA 
(10min at RT) while still inside the culture plates. This was followed by three quick 
washes with PBS and a permeabilisation step in 0.1% Triton X-100 (Sigma-Aldrich), 
followed by another three PBS washes. After blocking with 4% normal goat serum 
(NGS; Sigma Aldrich) for 30 minutes  at RT, the coverslips were taken out of the 
culture plate and transferred upside down unto 100µl drops of primary antibody 
solution which consisted of the respective antibody, or two antibodies in case of co-
staining, in 4% NGS (Table 12). The cells were incubated with the primary antibody 
overnight at 4°C, washed three times with PBS and incubated with secondary 
antibodies in blocking solution (Table 13) for 2 hours at RT (still as inverted drop 
setup). After a last set of three PBS washes (the first one containing 0.1 µg/ml DAPI 
in PBS for 5 minutes) the coverslips were mounted with Shandon Immu-Mount 
(Thermo Fisher) mounting medium on microscopy slides, air dried at RT and then 
stored at 4°C until imaging. 
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In case of imaging cells treated with fluorescent nanopolymers, DAPI got replaced by 
10µM DRAQ5 (BioStatus / ExOmax= 600nm; EmOmax= 694nm) as nuclear counterstain 




2.5.3. Immunohistochemistry (IHC) 
 
For antibody staining on sections, the initial steps are different depending on 
whether the sections are cryo or paraffin. Cryo sections were taken from -80°C and 
brought to RT, before they were hydrated in de-ionised water, fixated with ice-cold 
Methanol/Acetone (1:1) for 5 minutes and washed three times in PBS. Paraffin 
sections were de-paraffinised and rehydrated as described above (“Histological 
Staining”) before undergoing an antigen retrieval procedure by being incubated in 
trypsin-EDTA for 30 minutes at 37°C. The slides were then washed three time in PBS 
and thereby brought back to RT. The remaining steps were identical for both cryo 
and paraffin sections. After blocking of the sections with 4% NGS for 2 hours at RT, 
they were incubated with the primary antibodies (up to two antibodies of different 
host species together in blocking solution) overnight at 4°C.  The sections were 
washed three times with PBS and then incubated with secondary antibodies (in 
blocking solution) for 1 hour at RT. The first of the following three PBS washes (5 
minutes each) contained 0.1 µg/ml DAPI as nuclear counterstain; subsequent to this 
step the sections were mounted, covered by glass cover slips and air dried at RT 
before being stored at 4°C until imaging. Cryo sections of nanopolymer- or LY-treated 
samples were fixated in the same way as for other stainings and then directly 
counterstained with 10µM DRAQ5 for 5 minutes at RT before being washed twice in 









ICC and IHC stainings were imaged using either a Leica DM500B epifluorescence 
microscope with MetaMorph Basic (Molecular Devices) or Zeiss 710 Z2 laser scanning 
confocal microscope with ZEN (Zeiss). Images were taken at 100x to 630x 
magnification using the same acquisition settings for all samples of one set. Post-
processing of the images was performed with ImageJ v1.50b (National Institute of 
Health, USA). 
 
2.6.1. Quantitative Image Analysis of Penetration on Skin and Organotypics 
 
For the quantitation of nanopolymer penetration into treated tissue samples images 
of nuclear counterstained cryo sections were analysed in ImageJ. In a first step the 
epidermal area of interest was defined via nuclear staining (discarding outlying 
fluorescence of stratum corneum and dermis) and the green fluorescent signal 
isolated. The green signal was then transformed into a binary threshold image (using 
the same threshold for all the compared images), quantitated via particle analysis 
and related to the size of the epidermal area of interest (Figure 27).  
 
 
Figure 27: Quantification of green fluorescent signal for polymer penetration in cryo sections. 
For the quantification of nanopolymer localisation, first the epidermal area of interest (yellow line) 
was determined via the blue DRAQ5-staining of keratinocyte nuclei. In this area the green channel 
was isolated and transformed into a binary threshold image which could then be quantified in relation 
to the area size. 
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2.6.2. Quantitative Image Analysis of Colocalisation in Monolayer Cells 
 
Colocalisation analysis of fluorescent nanopolymers with antibody-stained 
compartments in monolayer keratinocytes was performed in ImageJ by using two 
specialised plugins:  JACoP (Bolte and Cordelières 2006) and Intensity Correlation 
Analysis (http://wwwfacilities.uhnresearch.ca/wcif/imagej/colour_analysis.htm).  
For the analysis, 630x magnified image stacks (8 single images in 0.5µm intervals 
along the z-axis) were taken on the Zeiss 710 Z2 and underwent analysis in parallel 
using the same thresholds and parameters for all compared samples.  
By using the specialised plugins, several coefficients were generated for the 
individual images. Pearson Coefficient (PsCo) (Manders et al. 1992) and Li’s Intensity 
Correlation Quotient (Li’s ICQ) (Li et al. 2004) are general co-localisation coefficients 
that correlate intensity spikes in the red and green channel of the image and express 
the global degree of colocalisation in a single numeric value (-1 to 1 for Pearson and 
-0.5 to 0.5 for Li, with positive values indicating a degree of colocalisation and 
negative values exclusion) . Manders Coefficients 1 and 2 break down the fraction of 
co-localising pixels for each channel individually, allowing for a separate analysis of 
the two co-localising elements (Manders et al. 1993).  
 
 
2.7. Western Blotting 
 
In order to perform quantitative protein expression analysis on monolayer cells 
established western blotting protocols were used. As a first step protein lysates from 
monolayer cells were acquired by using a specified lysis buffer (Table 9). Culture 
plates with confluent cells were put on ice and washed twice with ice cold PBS before 
adding 90 °C hot lysis buffer (100 µl per x cm2). The cells were scraped off and 
pipetted with the lysis buffer into eppendorf tubes before aliquoted and stored at  
-80 °C. Protein concentrations were determined using a Bradford assay kit (Bio-Rad 
protein assay) according to manufacturer’s instructions. Running and stacking gels 
(Table 10) were sequentially prepared (15wells per gel) and lysates loaded into them 
at 30µg protein per well. Prior to the loading the lysate aliquots were transferred 
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directly from -80°C unto a heating block at 95°C and kept at this temperature for 
5min for further denaturation of the proteins. The loaded gels were run in running 
buffer (Table 11) and at 12mA per gel (up to two gels per running tank) until proteins 
were sufficiently resolved, judged by the co-loaded protein marker (Amersham 
Rainbow Molecular Weight Marker, GE Healthcare). Proteins were subsequently 
transferred unto nitrocellulose membranes in transfer buffer (Table 11) at 4°C over 
night (80mA per transfer tank). Protein-containing membranes were then blocked 
with 5% milk powder in PBST (PBS + 0.05% Tween-20) before being cut into 
appropriate segments and incubated with the individual primary antibodies (Table 
12) over night at 4°C. After washing the membranes three times with PBST (10 
minutes each time) horseradish peroxidase(HRP)-conjugated secondary antibodies 
(Table 13) were incubated on the membranes for 2 hours at RT, followed by another 
three washing steps. Stained protein bands were then detected by using Immobilon 
ECL Substrate (Millipore) and the ChemiDoc MP System (Bio-Rad) according to the 
manufacturer’s instructions. Comparative quantitation of imaged bands was 
performed via ImageJ (integrated gel analysis tool).   
 
 
2.8. Statistical Analysis 
 
Where applicable, error bars in graphs denote the standard deviation for three 
independent measurements as part of one single experiment (i.e. ‘technical 
replicates’).  
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Table 9: Composition of lysis buffer 
Ingredient Supplier Final concentration 
Tris Sigma-Aldrich 1 M 
Sodium chloride Sigma-Aldrich 2.5 M 
Glycerol Sigma-Aldrich 10 % 
Glycerophosphate Sigma-Aldrich 0.5 M 
Tween-20 Sigma-Aldrich 1 % 
Nonidet P40 Sigma-Aldrich 0.5 % 
cOmplete¥ Protease 
inhibitor (EDTA-free) Sigma-Aldrich 1 tablet per 50 ml 
 
 











Diagnostic 12 % 5 % 
Tris-HCl (pH 6.8) BioVision --- 0.13 M 
Tris-HCl (pH 8.8) BioVision 0.375 M --- 
SDS Sigma-Aldrich 1 % 
Ammonium 
persulfate Sigma-Aldrich 1 % 
TEMED Sigma-Aldrich 0.1 % 
 
 








Tris-HCl (pH 8.9) Sigma-Aldrich 25 mM 
Glycine Sigma-Aldrich 190 mM 
SDS Sigma-Aldrich 0.1 % --- 
Methanol Sigma-Aldrich --- 20 % 
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Table 12: List of primary antibodies 
Marker protein Host species Supplier Product no. Concentration (ICC / IHC) 
Concentration 
(WB) 
ABCA 1 rabbit Abcam ab125064 1:500 1:1000 
ABCA 12 rabbit Abcam ab98976 1:100 1:1000 
ADAM 17 rabbit Abcam ab2051 1:100 n/a 
Connexin 26 (Cx26) mouse Thermo Fisher 13-8100 1:200 n/a 
CK10 mouse Abcam ab9025 1:200 1:1000 
CK14 mouse CRUK LL001 1:50 1:1000 
CK16 rabbit Abcam ab76416 1:200 n/a 
EGFR rabbit Abcam ab2430 1:50 n/a 
GAPDH rabbit Abcam ab9485 n/a 1:1000 
GM130 rabbit Abcam ab52649 1:100 n/a 
Involucrin mouse Abcam ab68 1:100 1:1000 
iRHOM2 rabbit Sigma-Aldrich HPA018080 1:200 n/a 
Ki67 rabbit Abcam ab15580 1:500 n/a 
LAMP2 mouse Abcam ab25631 1:100 n/a 
TGN46 mouse Abcam ab2809 1:200 n/a 
TGM1 rabbit Sigma-Aldrich HPA040171 1:200 1:1000 
Vinculin rabbit Abcam ab125064 n/a 1:2000 
 
Table 13: List of secondary antibodies 
Target species Conjugate Host species Supplier Product no. Concentration (ICC / IHC) 
Concentration 
(WB) 
mouse Alexa 488 goat life technologies A21121 1:600 n/a 
mouse HRP goat DAKO P0447 n/a 1:4000 
rabbit Alexa 546 goat life technologies A11010 1:600 n/a 
rabbit HRP goat DAKO P0448 n/a 1:4000 








A first necessary step of the project was the identification of a suitable protocol for 
the organotypic culture of various immortalised keratinocyte cell lines. Different 
approaches regarding the supporting matrix were hereby used with the aim of 
producing a viable skin equivalent, the quality of which was judged through the 
comparison with explant skin cultures as a gold standard (Figure 28). Since the model 
has to be suitable for the assessment of topical compound applications, focus was 
placed on a variety of supra-basally expressed differentiation markers such as CK10, 
Involucrin and TGM1. In addition, the highly fluorescent, hydrophilic dye Lucifer 
Yellow was topically applied to samples in order to perform a functional assessment 
of the permeability barrier, with the dye solution being retained in the stratum 
corneum of the treated sample in the presence of a functional epidermal 
permeability barrier. Proliferation markers of the more basal layers such as CK16 and 
Ki67 were also used to assess the possibility of modelling hyperproliferative skin 
diseases.  
 
3.1.2. Alvetex-based Model 
 
The first attempt at generating an organotypic keratinocyte culture involved the 
application of commercially available Alvetex culture inserts: 200µm thick, porous 
polystyrene scaffold for the seeding and subsequent submerged or airlift culture of 
cells. Initially, a variety of culture periods were used to generate epidermal (only 
containing immortalised K17 keratinocytes) and dermal-epidermal (combination of 
primary human fibroblasts and K17 keratinocytes) equivalents, using histological 
H&E staining to assess the resulting models (Figure 29). Epidermal equivalents were 
cultured for one (Figure 29 a), two (Figure 29 b) and three weeks (Figure 29 c) in airlift 
conditions. A visible onset of an eosinophilic red stratum corneum-like upper layer  








Figure 28: Protein marker expression and barrier function in explant skin 
Explant skin that has been kept in a tissue culture incubator (37°C; 5% CO2; humidified) for up to 48 
hours shows a typical expression of marker proteins. Differentiation-associated CK10 and Involucrin 
are expressed suprabasally and TGM1, as a marker for terminal differentiation, can be found in the 
uppermost layers of the epidermis. Proliferation markers CK16 and Ki67 are restricted to the lower 
epidermal layers (disregarding a false background staining of the stratum corneum in case of Ki67). 
The topically applied green fluorescent dye Lucifer Yellow is entirely retained by the stratum 
corneum. Scale bar represents 50µm. 
Results: Organotypic Model 
 66 
was detected after two weeks but no striking signs of layering / stratification of the 
keratinocytes inside the Alvetex scaffold. Dermal- epidermal models were generated 
through the initial seeding of fibroblasts in the scaffold followed by the addition of 
keratinocytes after a set culture period and subsequent culturing of the combined 
model. The pre-incubation of fibroblast for one week seemed to generally yield 
viable models with visible incorporation and stratification of added keratinocytes. 
Whereas the subsequent culture of the combined model for one additional week 
resulted in an even distribution of keratinocytes across the scaffold and appearance 
of flattened cells building up an uppermost stratum corneum-like layer (Figure 29 d), 
the elongation of the combined culture period to three weeks increased this effect: 
keratinocytes appeared to settle mostly in the upper parts of the scaffold and the 
uppermost layer was more pronounced and included first signs of shedding as well 
(Figure 29 e). An initial three week-culture of fibroblast followed by the addition of 
keratinocytes for another week did not seem to result in a viable equivalent, with 
minimal signs of incorporated keratinocytes (Figure 29 f). 
After narrowing down the culture conditions to a few promising alternatives, one of 
the combinations (one week of fibroblasts followed of three weeks of combined 
culture) was further assessed in regards to marker expression and permeability 
barrier function (Figure 30). The pattern of differentiation-associated protein 
expression appeared to be tendentially right, with the basal marker CK14 being 
restricted to the lower parts of the epidermal portion of the organotypic and 
Involucrin being mostly expressed in the uppermost layers. However, the topically 
applied Lucifer Yellow though was exclusively found in the bottom part of the 
organotypic, indicating a diffusion of the dye throughout the organotypic and 








epidermal equivalent  
(only keratinocytes) 
dermal-epidermal equivalent 






Figure 29: Histology of Alvetex-based organotypic after different incubation times 
Epidermal equivalents, containing only keratinocytes, were cultured for one (a), two (b) and three 
weeks (c) under airlift conditions. H&E staining indicates an increasing degree of stratification in the 
upper layers over time. Different combinations of dermal-epidermal equivalents were tested: one 
week of fibroblasts followed by another week after the addition of keratinocytes (d), one week of 
fibroblasts followed by three weeks after the addition of keratinocytes (e) and three weeks of 
fibroblasts followed by one week of keratinocytes (f); resulting in vastly different histologies as a 
result. Scale bar represents 100µm. 
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3.1.3. Collagen-based Model (Normal Phenotype) 
 
Due to the Alvetex-based model not forming a functioning epidermal permeability 
barrier, another approach using a collagen 1-scaffold with incorporated fibroblasts 
as dermal equivalent to seed epidermal keratinocytes on was used. Applying this 
model on the same K17 keratinocytes resulted in a superior organotypic in regard to 
histology and barrier function (Figure 31). The epidermal portion of the organotypic 
displayed an epidermis-like arrangement of keratinocytes, with signs of different 
Figure 30: Marker expression and permeability barrier in Alvetex-based organotypics 
Alvetex-based epidermal equivalents were cultured for two weeks in airlift conditions and 
subsequently tested for expression of protein markers and the presence of a permeability barrier. 
Basal marker CK14 was found in the lower parts of the organotypic and differentiation marker 
Involucrin mostly restricted to the uppermost layers. Traces of the topically applied dye Lucifer 
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layers due to change in orientation of the stacking cells from vertical to horizontal 
and the build-up of an anucleated, strongly eosinophilic upper layer similar to the 
stratum corneum in skin explants. Consequently, topically applied Lucifer Yellow was 
retained in this uppermost layer of the organotypic, again similarly to the retention 
of the dye in the stratum corneum of explant skin. 
 
Subsequently, the collagen-based model was used in conjunction with a variety of 
immortalised keratinocyte control cell lines (K17, HaCaT, nTERT, NEB1) as well as 
primary keratinocytes. The resulting organotypics were very different when it came 
to general histology of the epidermal portion and expression of selected marker 
proteins (Figure 32). Regarding the histology of the various organotypics the most 
striking difference is the degree of invasion of keratinocytes into the underlying 
dermal collagen part and connected to this the presence of a defined basal layer.  
Whereas nTERTs show no signs of invasion and display a lowermost layer of cuboidal, 
vertically oriented keratinocytes, HaCaTs and NEB1s have islets of invading cells in 











Figure 31: Histology and barrier function in explant skin and normal-phenotype organotypic 
Organotypics based on immortalised normal keratinocytes show a layered, stratified arrangement of 
cells including an eosinophilic, anucleated uppermost layer, similar to the epidermal structure of 
control skin. Topically applied green fluorescent Lucifer Yellow is retained by the uppermost layer of 
the organotypic as well as the stratum corneum of explant skin. Scale bar represents 50µm. 
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addition to a fairly defined lowermost layer and primary keratinocytes appear with a 
more bulk-like invasion including a basal layer inside these bulks. K17 cells on the 
other hand tended to result in a rather disorganised, invasive phenotype. NEB1s that 
were grown directly on top of a PET membrane, without the addition of a dermal 
component, again display a histologically defined basal layer.  
Signs of terminal differentiation into a stratum corneum-like uppermost layer also 
varied between the different organotypics. K17s resulted in a defined, strongly 
eosinophilic layer on top but this only occured to a lesser degree in primary 
keratinocytes and NEB1s, though the omission of the dermal component does seem 
to increase the stratification in the latter. HaCaTs and nTERTs show an onsetting 
flattening of cells in the uppermost layers. A common feature of all of the organotypic 
models is the tendency for epidermal thickening to varying degrees, with epidermal 
portions being comprised of more layers of keratinocytes than is typical for 
interfollicular skin. In regard to the differentiation-associated marker protein CK10, 
HaCaTs and NEB1s show an expression throughout the suprabasal layers of the 
epidermal portion while primary keratinocytes, K17s and NEB1 (without collagen) are 
more restricted towards the upper layers. Involucrin as another differentiation 
marker is suprabasally expressed in all the various organotypics. The more terminal 
differentiation-associated enzyme TGM1 is also expressed in all organotypics but 
whereas it is mostly restricted to upper layers in primary keratinocytes, K17, nTERT 
and NEB1 (without collagen) HaCaTs and NEB1s show a strong expression throughout 
all suprabasal layers. The hyperproliferation marker CK16 is predominantly found in 
the lower layers of primary keratinocyte, K17, HaCaT and nTERT organotypics.  
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In addition to comparing different cell lines in the organotypic model, organotypics 
for selected cell lines (K17, HaCaT, NEB1 with or without collagen scaffold) were 
cultured for one and two week periods in airlift conditions in order to track and 
compare the change of histology and differentiation marker expression over time 
(Figure 33). Histologically all the organotypics appear to develop a thickened 
epidermal portion in between day 7 and day 14 together with an increased degree 
of stratification in the upper layers. This is accompanied by a consolidation of 
differentiation markers CK10 and Involucrin, namely an increase in expression levels 
and/or spatial shift towards upper layers. TGM1 also displays a general increase in 
expression over time which in the case of HaCaT, NEB1 and to some degree K17 is 
combined with a spreading towards lower suprabasal layers. In the NEB1 
configuration without a dermal equivalent TGM1 gets more restricted towards the 
uppermost layer of the organotypic after 14 days. K17 and HaCaT-derived 
organotypics display an increase in CK16 expression whereas NEB1 organotypics do 
not express CK16 even after 14 days of culture. Overall, despite general differences 
in histology and marker expression, all the various organotypics appear to show signs 
of increased differentiation and stratification when prolonging the culture time from 
7 days to 14 days. 
Figure 32: Differences in histology and marker expression between normal-phenotype organotypics 
Organotypics based on primary keratinocytes and a variety of normal, immortalised keratinocyte cell 
lines (K17, HaCaT, nTERT, NEB1) display striking differences in the expression of protein markers for 
differentiation (CK10, Involucrin, TGM1) and hyperproliferation (CK16). Scale bar represents 50µm. 
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3.1.4. Characterisation of Monolayer Keratinocytes in different Media 
 
Since the use of different keratinocyte cell lines in the organotypic model yielded 
very varied results regarding the expression of marker proteins, monolayer cultures 
for K17, HaCaT, NEB1 and primary keratinocytes were stained for several protein 
markers and compared while also recapitulating the change from maintenance to 
differentiation medium which is part of the protocol for the generation of 
organotypic cultures (Figure 34). Brightfield images revealed similar changes in cell 
morphology as result of the medium switch: after the switch cells generally show a 
more flattened shape and presence of granules in the cytoplasm, with a more 
pronounced effect in primary keratinocytes which already start off in more flattened 
morphology. In regard to marker expression, K17 cells in maintenance culture have 
virtually no expression of differentiation markers CK10 and Involucrin, moderate 
levels of differentiation marker Loricrin and proliferation-associated Ki67 and 
ubiquitous expression of basal marker CK14 and hyperproliferation marker CK16. 
During the switch to differentiation medium this changes with a slight increase in the 
number of Ki67-positive cells, a stronger restriction of CK14 to the edge of colonies 
and the appearance of single Involucrin-positive cells. In the case of HaCaT cells there 
appears to be an increase in Loricrin and Involucrin-positive cells through the 
medium switch accompanied to a similar redistribution of CK14 expression as seen 
in K17 cells. NEB1 cultures displayed an increase in the number of CK10 positive cells 
whereas Involucrin and Loricrin seems mostly unaffected. Ki67 is more abundant 
after the medium switch while CK14 is absent before or after. Similarly, CK16 levels 
are very low compared to the other two cell lines. In primary keratinocyte cultures 
the switch to differentiation medium seems to induce a reduction in Ki67-positive 
cells and an increase in Involucrin expression. 
Figure 33: Changes in protein expression of normal-phenotype organotypics over culture time 
All keratinocyte cell line-based organotypics (K17, HaCaT, NEB1) exhibit a general upregulation and/or 
restriction to suprabasal layers of differentiation-associated markers (CK10, Involucrin, TGM1) in 
between 7 and 14 days of airlift culture. In the case of K17 and HaCaT this is accompanied by an 
increased expression of CK16 in the lower parts of the organotypic. All organotypics display signs of 
increased stratification in histological stainings with culture time. Scale bars represent 50µm. 
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Already high levels of CK14 and CK16 during maintenance culture appear to be 
mostly unaffected by the medium switch, which also applies to the moderate levels 
of Loricrin expression. Overall, while all the keratinocyte cultures have strikingly 
different protein expression patterns in general, there does appear to be a common 
trend towards a more differentiation-associated phenotype as a result of the 
medium switch.  
 
 
3.1.4. Summary and Discussion 
 
Two different scaffold-based systems were applied in this project with the aim to 
establish a viable in vitro skin equivalent using organotypic cultures of immortalised 
keratinocytes. In an initial approach the commercially available Alvetex polystyrene 
scaffold was used. While this model has been published in a variety of tissue 
engineering applications (Liu et al. 2013; Caiazza et al. 2015; Li et al. 2015; Smith et 
al. 2015) there is only singular evidence for its use as an epidermal model, while using 
only early-passage primary keratinocytes in this case (Sharma et al. 2013; Hill et al. 
2015). Several combinations of co-culturing fibroblasts and keratinocytes as well as 
culturing keratinocytes on their own were therefore attempted in order to narrow 
down an optimised protocol for the generation of skin equivalents with in this 
system. Even though the best combinations yielded a degree of layering and 
stratification in the epidermal portion, both visible in the histology as well as the 
expression of marker proteins CK14 and Involucrin, the likeness to actual skin 
explants was still sub-optimal. Furthermore, none of the generated organotypics 
resulted in the retention of a topically applied aqueous Lucifer Yellow solution, a 
widely used method for the assessment of a functional epidermal permeability 
Figure 34: Medium-dependant changes in protein expression of monolayer keratinocytes 
After switching from maintenance medium to differentiation medium for 48 hours, monolayer 
keratinocytes show similar trends in regard to changes in protein expression: one or more 
differentiation markers (CK10, Loricrin, Involucrin) are mostly upregulated and CK14 is slightly 
restricted to the proliferative edges of colonies. Proliferation markers Ki67 and CK16 seem mostly 
unaffected by the medium switch. Scale bars represent 100µm. 
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barrier (Blaydon et al. 2011; Frankart et al. 2012; Bachelor et al. 2014; Pendaries et 
al. 2014). Apart from insufficient terminal differentiation of keratinocytes in this 
specific model, this might also be due to the presence of the non-degradable 
polystyrene fibres as essential constituent of the Alvetex scaffold. Epidermal barrier 
function is strictly dependant on the tight physical connection of the corneocytes and 
keratinocytes in the upper layers of the epidermis (i.e. stratum corneum and upper 
stratum granulosum), both through intercellular contacts such as tight junctions and 
extracellular lipid and protein envelopes (Proksch et al. 2008; Brandner et al. 2010; 
Kirschner et al. 2010). It is therefore feasible to assume that the polystyrene fibres 
interrupt these connections and provide a way for aqueous solutions to diffuse 
throughout the organotypic. Since a functional permeability barrier was essential for 
the model in regard for its later application (see Chapter 3.4), this finding was enough 
to exclude the Alvetex-based system from further applications. Consequently, 
collagen-based culture models were approached as an alternative since their 
application as skin equivalents and for the in vitro modelling of skin diseases has been 
widely established (Mildner et al. 2006; Alnasif et al. 2014; Eckl et al. 2014).  
In the context of this project several keratinocyte cell lines from different origins have 
been applied in the collagen-based model: HaCaT is a spontaneously immortalised 
cell line (Boukamp et al. 1988), nTERT cells are based on the induced overexpression 
of telomerase reverse transcriptase (Lee et al. 2004) and K17 / NEB1 were generated 
through transfections with HPV16 E6/7 genes (Storey et al. 1988). Even though the 
majority of published applications is based on using primary keratinocytes (Mildner 
et al. 2010; Bogaard et al. 2013; Gschwandtner et al. 2013; Alnasif et al. 2014) there 
are also cases of immortalised keratinocytes being used, though with varying success 
possibly due to the different cell lines being used (Boelsma et al. 1999; Schoop et al. 
1999; Allen-Hoffmann et al. 2000; Skazik et al. 2014; Reijnders et al. 2015). The 
application of immortalised cell lines in the attempt of recapitulating physiological 
features in vitro can potentially be problematic since different approaches of 
immortalisation can result in distinct genomic and phenotypic changes. While hTERT 
cells have been repeatedly used in the generation of normal looking skin equivalents 
(Dickson et al. 2000; Man et al. 2007; Reijnders et al. 2015), HaCaT cells on the other 
hand were shown to display deficits in regard to (terminal) differentiation and 
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hyperproliferation characteristics (Schurer et al. 1993; Boelsma et al. 1999; Schoop 
et al. 1999; Micallef et al. 2009). Furthermore, expression of HPV16 E6/7 genes in 
keratinocytes has been widely associated with hyperproliferation, invasion and an 
overall disordered, premalignant phenotypes in organotypic models (Blanton et al. 
1991; Boxman et al. 2001; Delvenne et al. 2001; Pickard et al. 2015; Srivastava et al. 
2015). These previous studies seem to mostly correspond with the results of the 
different cell line-derived organotypics. In addition, a prolonged overall culture life-
time which is the case in all keratinocyte cell lines and even in high-passage primary 
keratinocytes, such as the ones that have been used as controls in the establishment 
of the organotypic protocol, can also lead to wide-ranging genomic changes and 
aberrant cell behaviour which might further add to the problematic (Maitra et al. 
2005; Binato et al. 2013; Bentivegna et al. 2016). Consequently, when using a variety 
of cell lines as well as high-passage primary cells in the established organotypic 
model, the results were strikingly different in regard to protein expression, invasion 
and stratification. Even before the application in the more complex three-
dimensional model, monolayer cultures already showed diverse protein expression 
patterns, underlining the phenotypic differences between the various cells (which 
could potentially be compared in more detail by quantitation of cells positive for 
proliferation or differentiation marker across the different cell lines and conditions). 
Even though low-passage primary cells are generally preferable for the generation of 
skin equivalents, there are still distinct advantages in using immortalised cell lines, 
especially when it comes to the prolonged availability of rare patient-derived and 
therefore disease-relevant cell material (Thomas et al. 2009; Blaydon et al. 2013; 
Brooke et al. 2014). Furthermore, all applied cells successfully recapitulated 
epidermis-like features in the organotypic culture model (including the presence of 
a functional permeability barrier) and displayed common reactions to changes in the 
culture protocol, such as the increased differentiation phenotype due to medium 
switch and prolonged culture time.  
Therefore, the possibility of using immortalised keratinocytes for in vitro skin 
equivalents is still justifiable as long as the distinct characteristics of each cell line are 
taken into consideration when choosing a suitable model for a specific application, 
such as the ability to build a viable permeability barrier for the assessment of topical 
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polymer delivery (Chapter 3.4) or a similar genetic background due to same 
immortalisation protocol when comparing normal and disease-related phenotypes 
(Chapter 3.2).    
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After establishing a model for the generation of normal-phenotype in vitro skin 
equivalents through organotypic keratinocyte culture on collagen scaffolds, the next 
step of the project involved the application of patient-derived keratinocyte cell lines 
in order to recapitulate disease phenotypes in the in vitro model. For this purpose, 
cell lines for two hereditary skin disorders were used: Harlequin Ichthyosis (Chapter 
1.2.1) and Tylosis (Chapter 1.2.2). Since those two cell lines were immortalised using 
HPV16 E6/7 genes, K17 was used as a normal-phenotype control, having been 
immortalised around the same time, in the same lab and with the same protocol 
(Storey et al. 1988). After having successfully established a distinct disease 
phenotype for each model, by comparing with known and published features for 
each disorder, it was then attempted to manipulate these phenotypes through 
shRNA interference or specific small-molecular compounds aimed at disease-
relevant pathways. Successful application of TOC-specific compounds was then 
replicated in another disease model for Pachyonychia congenita (Chapter 1.2.3), 
since this disorder is caused by dominant mutations in the gene for CK16 which is 
implicated to be functionally connected to the TOC-relevant iRHOM2-ADAM17-EGFR 
pathway (Maruthappu et al. 2016). 
 
3.2.2. Characterisation of Cutaneous Disease Models 
 
Striking histological differences were found in the skin equivalents based on HI and 
TOC keratinocytes in comparison to the normal-phenotype K17-derived organotypic 
(Figure 35). While K17-based organotypics show a normal skin-like histology, HI 
organotypics display signs of hyper- and parakeratosis: the uppermost, stratum 
corneum-like layer is severely thickened in comparison to the normal model and 
seems to contain a higher amount of nuclei. TOC organotypics also show signs of 
parakeratosis, in addition to having a highly disorganised and abnormally thickened, 
hyperproliferative epidermal portion.  












Figure 35: Histological differences in between normal and disease organotypics 
Organotypics based on normal as well as patient-derived keratinocytes were cultured for two weeks 
in airlift conditions and subsequently compared in their histology, displaying distinct differences. HI 
organotypics exhibit a thickened, nucleated stratum corneum, whereas TOC organotypics show a 
hyperkeratotic, disorganised arrangement of the epidermal portion in comparison to the normal-
phenotype control organotypic. Scale bar represents 50µm. 
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Subsequently, when examining the hyperproliferation-associated protein marker 
CK16, further differences can be seen in between the normal and disease models 
(Figure 36). Whereas the K17-based organotypics show a slight expression of CK16 in 
the more basal layers of the epidermal portion, this expression is distinctly 
upregulated in the HI model and even more so in the TOC organotypic. Additionally, 
in case of TOC the expression of CK16 seems to be found throughout all suprabasal 
layers of the epidermal portion.  
 
Figure 36: Different hyperproliferation phenotype in normal and disease organotypics 
Organotypics for Harlequin ichthyosis and Tylosis show a strongly increased suprabasal expression of 
hyperproliferation-associated CK16, compared to normal-phenotype organotypics. Scale bar 
represents 50µm. 
 
When looking into more detail for the individual disease models, the HI-based 
organotypic displays a reduction of the membrane transporter ABCA12 and an 
upregulation / earlier onset of the differentiation marker Involucrin (Figure 37 a). Nile 
Red staining though shows no visible imbalance of polar (red) and non-polar (green) 
lipids when compared to the normal phenotype organotypic, which can also be 
confirmed in matched patient skin sections (Figure 37 b).  
In case of the TOC model, immunohistochemistry reveals a strong upregulation of 
inactive rhomboid protease iRHOM2 across suprabasal layers in comparison to the 
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3.2.3. Manipulation of a Harlequin Ichthyosis Model 
 
After establishing a distinctly different disease phenotype for the HI model, two 
small-molecular PPARG and LXR agonists (GW0742 and TO901317 respectively) were 
applied in order to try to counteract disease-specific mechanisms through 
upregulation of ABCA1. As first step the compounds were used on monolayer HI 
keratinocytes in order to verify the intended effect. Both compounds result hereby 
in similar changes for the treated cultures, first in general upregulation of membrane 
transporter ABCA1 and trans-Golgi marker TGN46 (staining lamellar granules) and 
then in the decrease of Involucrin-positive cells (Figure 39). 
Subsequent to characterising the effect of both compounds in monolayer cells, they 
were then applied to HI organotypics by supplying them via the culture medium for 
the last 10 days of airlift culture, treating control HI and K17 organotypics with equal 
doses of the DMSO solvent. Both compounds showed hereby distinct effects on 
histology and protein expression of the HI organotypics (Figure 40). While the 
untreated HI sample displayed expected features, such as hyper- and parakeratosis, 
upregulation of Involucrin and downregulation of ABCA1 and ABCA12, treatment 
with GW0742 lead to a reduced disease phenotype and features more resembling 
the ones seen in the K17-based control organotypic: the stratum corneum was 
slightly reduced in thickness and with less retained nuclei and Involucrin slightly less 
expressed.   
Figure 37: Phenotypical features of HI organotypics 
Organotypics based on keratinocytes from patients with HI display an overall reduction in the 
expression of membrane transporter ABCA12 accompanied by an upregulation of differentiation 
marker Involucrin (a) compared to organotypics from normal keratinocytes. Nile red staining on the 
other hand reveals a similar lipid profile between normal and HI, without the typical absence of non-
polar lipids (green) in the case of HI. Parallel staining of the corresponding patient skin sample 
reproduces this finding (b). Scale bar represents 50µm. 
 











Figure 38: Differential protein expression in normal and TOC organotypics 
Two-week old organotypics from TOC keratinocytes show a strong upregulation of iRHOM2 and EGFR 
compared to the corresponding normal-phenotype organotypics. Scale bar represents 50µm. 
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The expression of ABCA1 was increased similar again to levels in the K17 sample 
whereas the reduction in ABCA12 appeared unchanged. In regard to the TO901317-
treated sample, the epidermal portion appeared to be severely disrupted and ABCA1 
drastically upregulated both in comparison to the HI as well as the K17 sample. 





















Figure 39: Compound-driven modulation of HI-specific features in monolayer cells 
Patient-derived keratinocytes were cultured in monolayer, treated for two days with small molecular 
compounds and then stained for HI-specific protein markers. Both compounds, PPAR∂-agonist 
GW0742 (10µM) and LXR-agonist TO901317 (8µM), resulted in an upregulation of membrane 
transporter ABCA1 and trans-Golgi component TGN46, whereas differentiation-associated Involucrin 
seemed less expressed with the treatment. Scale bar represents 50µm. 
 




3.2.4. Manipulation of a Tylosis Model via shRNA-knockdown of iRHOM2 
 
One possible way of counteracting the TOC-related phenotype in cells and 
organotypics, due to the dominant iRHOM2 mutation, was approached via 
introduction of a stable shRNA-based knockdown of iRHOM2 (this and the resulting 
experiments were done in cooperation with Dr Thiviyani Maruthappu and Dr Anissa 
Chikh, Blizard Institute, QMUL). The knockdown led to a stable 57% reduction of 
iRHOM2 protein in TOC keratinocytes (Figure 41 a) and a concomitantly reduced 
iRHOM2 staining in organotypics derived from these cells. This was accompanied by 















Figure 40: Compound-driven modulation of HI-specific features in organotypics 
HI organotypics were treated with two small-molecular compounds, PPAR∂-agonist GW0742 (10µM) 
and LXR-agonist TO901317 (8µM), while grown in parallel to K17 organotypics as normal-phenotype 
control. GW0742 appears hereby to partially shift the aberrant HI phenotype towards the phenotype 
of the K17 control: the uppermost stratum corneum seems slightly reduced and less parakeratotic, 
ABCA1, which was strikingly reduced in the HI organotypic, was upregulated to similar levels as in K17 
and the HI-specifically overexpressed Involucrin seems to be slightly downregulated. ABCA12, being 
naturally less expressed in HI, does not appear to be affected by the treatment with GW0742. In case 
of TO901317, ABCA1 expression was drastically increased and the overall structure of the epidermal 
portion seemingly disrupted. ABCA12 expression again appears mostly unaffected and Involucrin 
slightly upregulated. Scale bars represent 50µm. 
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a general reduction in thickness of the treated organotypic samples (Figure 41 b). The 
difference in iRHOM2 expression between control TOC organotypics and knockdown 
organotypics was similar in appearance to the different expression levels that can be 
found in TOC and healthy normal skin. In addition to generating organotypics the 
knockdown cells were further tested for hyperproliferation features in monolayer. 
Growth curves over 7 days showed a strikingly decreased reduction in proliferation 
of treated keratinocytes (Figure 41 c) and scratch assays also verified a reduction in 
migration with only a partial scratch closure after 18 hours (Figure 41 d). Since CK16 
as hyperproliferation-associated keratin is indicated to be regulated by its interaction 
with iRHOM2, expression levels were also checked both in monolayer and 
organotypics. The iRHOM2 knockdown resulted in a 47% reduction of CK16 
expression in comparison to control TOC cells (Figure 41 e). The reduction was also 
present in the derived organotypics and once again mirrored differences between 
TOC and normal skin (Figure 41 f).  
 
 
3.2.5. Manipulation of a Tylosis Model via compounds 
 
In addition to applying iRHOM2-targeting shRNA in order to manipulate the TOC 
phenotype in organotypics, another approach was based on the use of inhibitory 
compounds specific to components of the TOC-relevant iRHOM2-ADAM17-EGFR 
pathway. For this the EGFR-specific therapeutic antibody Cetuximab and the small-
molecular ADAM17 inhibitor TMI-005 were added to the medium supply of one-
week pre-cultured TOC organotypics and continuously supplied for the remaining 7 
days of airlift culture. The two treatment options had hereby differing effects on TOC 
features in the organotypic model (Figure 42). Whereas Cetuximab-treated 
organotypics did not display any obvious difference in regard to histology and 
expression of CK16, the TMI-005 treatment appeared to slightly alter the 
phenotypical features of TOC. H&E staining revealed a slight reduction in para- and 
hyperkeratosis in conjunction with a slight overall reduction in thickness for the 
epidermal portion.  
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Furthermore, CK16 expression was downregulated and spatially restricted towards 
the more basal layers of the organotypic in comparison to the control and Cetuximab-
treated samples.  
 
 
3.2.6. Manipulation of a Pachyonychia Congenita Model 
 
After the application of the ADAM17 inhibitor TMI-005 in TOC organotypics, the 
treatment approach was subsequently extended to another disease model based on 
keratinocytes from patients with Pachyonychia Congenita. The PC organotypics were 
hereby pre-cultured for two days in airlift culture before application of the 
compound via the medium supply for the remaining 12 days, resulting in a striking 
difference in regard to histology and protein expression of treated samples. While 
the histology for the untreated and DMSO control samples appeared disorganised 
and only moderately stratified, the inhibitor-treated organotypic was strikingly 
thinner, with a more distinguished basal layer and stronger stratification in the upper 
layers (Figure 43).  
Staining for protein markers in the PC control and TMI-005 samples further 
supported this initial observation through distinct changes in protein expression 
(Figure 44). In the treated sample both ADAM17 and iRHOM2 were severely reduced 
which was also accompanied by a decrease in Ki67-positive cells. In addition, CK16 
staining was slightly reduced and Involucrin slightly upregulated.  
Figure 41: Effect of shRNA-mediated iRHOM2 knockdown on TOC keratinocytes 
shRNA-mediated stable knockdown led to a strong decrease (57%) of iRHOM2 expression in Tylosis 
keratinocytes (a). The knockdown was still present in organotypics after two weeks of airlift culture, 
mimicking the difference in iRHOM2 expression between tylotic and healthy skin (b). In monolayer 
cultures the loss of iRHOM2 also resulted in a distinct decrease in proliferation (c) and migration (d) 
of knockdown cells. Furthermore, the iRHOM2 knockdown led to a subsequent reduction in 
expression of hyperproliferation-associated CK16 both in monolayer (e) and organotypics (f), where 
it again mirrors the differential expression in healthy and tylotic skin. 




3.2.7. Summary and Discussion 
 
Subsequent to establishing an organotypic culture model for immortalised normal-
phenotype keratinocytes, patient-derived cell lines were applied to the developed 
protocol in order to recapitulate disease phenotypes in vitro. While similar 
organotypic disease models have been done for a variety of disorders using primary 
keratinocytes derived directly from patients, optionally via the reprogramming of 






Figure 42: Inhibitor-treatment of TOC organotypics 
TOC organotypics were pre-cultured in airlift for one week before being supplied via the culture 
medium with inhibitors for EGFR (Cetuximab, 1µg/ml) and ADAM17 (TMI-005, 500nm) for the 
remaining 7 days. Organotypics treated with the therapeutic antibody Cetuximab showed hereby 
no visible effect on histology and expression of hyperproliferation marker CK16. The small-molecular 
inhibitor TMI-005 on the other hand seems to lead to a slight reduction in hyperkeratosis and 
restriction of CK16 to more basal layers. Scale bar represents 50 µm.  
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iPS cells (Barker et al. 2004; Jean et al. 2009; Bogaard et al. 2013; Umegaki-arao et al. 
2014), or by using cells treated with siRNA/shRNA to simulate disease-relevant loss-
of-function mutations (Mildner et al. 2006; Thomas et al. 2009; Eckl et al. 2011; 
Pendaries et al. 2014), the application of immortalised patient cell lines is a so far 
PC 
PC 
PC + DMSO 
PC + DMSO 
PC + TMI-005 
PC + TMI-005 
(a) 
(b) 
Figure 43: Histological changes in PC organotypics after application of ADAM17 inhibitor 
After culturing organotypics based on PC keratinocytes in the presence of ADAM17 inhibitor TMI-005 
for 10 days (first application at day 4 after airlift at 500nM) striking changes in the histology of the 
epidermal portion in comparison to the control and DMSO vehicle-treated samples can be seen (a): a 
visible reduction in thickness of the epidermal part is accompanied by a decreased invasion of 
keratinocytes into the collagen gel and a generally more structured arrangement of cells. This is in 
addition to a more prevalent eosin-stained uppermost layer, indicating a stronger terminal 
differentiation of the treated keratinocytes. Those changes can be observed throughout the whole 
diameter cross section of the organotypics (b). Scale bars represent 50µm. 
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lesser explored option. Using immortalised cells would provide certain advantages 
by making patient-specific cells, carrying (potentially dominant gain-of-function) 
disease mutations, available for long-term experimental series. Consequently, for 
this project, two different inflammatory disorders have been initially chosen in order 
to test the capacity of the model to mimic epidermal disease characteristics: 
Harlequin ichthyosis (Kelsell et al. 2005) and Tylosis with oesophageal cancer 
(Blaydon et al. 2012). The limited availability of rare disease material had hereby the 
consequence that a direct comparison of the modelled phenotype with patient skin 
was only possible in a few instances and had otherwise to be replaced by an 
assessment based on what has been previously described in the literature. In both 
disease models the combination of the organotypic model with patient-derived 
keratinocytes resulted in distinct changes in the histology and expression of 
hyperproliferation marker CK16. HI organotypics, although slightly variable in 
between batches as is the case for most of the cell-line based skin equivalents, 
generally showed pronounced signs of hyper- and parakeratosis, both typical 
features of HI (Rajpopat et al. 2011). A closer look at differentiation marker Involucrin 
further revealed the premature terminal differentiation phenotype which has 
already been described for HI (Thomas et al. 2009) and could be further investigated 
in the established model by using additional differentiation markers, e.g. Kallikreins. 
Despite these positive results though, other features were not reproducible in the 
model. Expression of ABCA12 was still present in the organotypics, although in 
reduced levels compared to controls, whereas HI skin classically shows a complete 
ablation of the protein (Akiyama 2005). This might be dependent on the specific type 
of mutation in the ABCA12 gene though and the loss-of-function mutation for this 
patient-derived cell line has been previously confirmed by Dr Philip Bland (Blizard 
Institute, QMUL) to be a splice site mutation that still produces a (non-functional) 
shortened protein. The observed reduction in expression might consequently be the 
result of a negative feedback loop mechanism (Scott et al. 2013). Another atypical 
feature of the disease organotypics was the presence of polar as well as non-polar 
lipids. Whereas HI skin should typically display a visible loss of non-polar ceramides 
as a result of the faulty packaging of lamellar granules via ABCA12 (Hovnanian 2005), 
the HI organotypics showed a balance of lipids similar to controls, which could 
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furthermore be also seen in the patient-matched skin sample. It was previously 
shown that HI patients undergo an improvement in their clinical features with age, 
towards a less severe, congenital ichthyosiform erythroderma-like phenotype 
(Rajpopat et al. 2011). Furthermore, a culture time-dependent self-improvement of 
HI keratinocytes in vitro, which also included a normalisation of their lipid profile, has 
been demonstrated before (Yanagi et al. 2010). It is therefore feasible to assume that 
the Nile Red results are due to the age of the (adult) donor as well as the prolonged 
overall culture of the derived keratinocytes.  
Even though the model did not reproduce all the features typical for HI skin, based 
on the features that could be replicated it was still deemed sufficient in assessing the 
effect of potential therapeutically relevant compounds. The activation of nuclear 
hormone receptors PPARG and LXR was hypothesised to improve HI-specific features 
by counteracting lipid imbalance in the upper suprabasal layers through enhanced 
cholesterol transport and subsequent secretion via membrane transporter ABCA1 as 
well as enhanced lamellar granule formation induced by AP-1 (Chawla et al. 2001; 
Schmuth et al. 2004a, 2004b; Jiang et al. 2006; Demerjian et al. 2009; Ouvrier et al. 
2009; Feingold and Jiang 2011). Consequently, two commercially available agonists 
for PPARG and LXR were applied to the HI model. Initial use in monolayer HI 
keratinocytes verified the intended effect by upregulating ABCA1 expression as well 
as increasing the presence of TGN46-positive lamellar granules. Additionally, 
Involucrin-staining showed a de-differentiating effect of the compound treatment 
which might be beneficial in regard to the pre-mature terminal differentiation 
phenotype that was already shown in the organotypic model. The subsequent 
application of the two compounds in the 3D model resulted in a visible disruption of 
the epidermal portion in case of the LXR agonist, possibly due to dose-dependent 
toxic side effects that did not became apparent in the monolayer culture (Götz et al. 
2012a, 2012b), and only subtle changes for the PPARG-specific compound despite the 
visible upregulation of ABCA1. This might be explained by the already discussed 
compensation of lipid imbalance by culture-time dependent mechanisms which 
would mask the effect of an increased ABCA1-induced cholesterol efflux in the upper 
layers.  
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TOC phenotypic features are based on gain-of-function mutations in the RHBDF2 
gene, encoding for the inactive rhomboid protease iRHOM2, and the resulting 
downstream upregulation of the EGFR pathway via increased ADAM17-dependent 
shedding (Brooke et al. 2014). A first approach in regard to trying to regulate these 
features included therefore the stable shRNA-mediated knockdown of iRHOM2 in 
TOC keratinocytes, the rational being that a partial loss in protein would counteract 
the gain of function (Maruthappu et al. 2016). Correspondingly, a stable knockdown 
in the monolayer cells translated in a still visible loss of expression in the organotypic 
culture after two weeks, accompanied by a striking loss in epidermal thickness. This 
finding was further supported by the striking reduction of migration and proliferation 
in treated monolayer cultures, which implies an overall loss in hyperproliferation 
features. Recently, a functional link between iRHOM2 and CK16 has been established 
by Maruthappu et al., with the stress- and hyperproliferation-associated CK16 being 
directly regulated by iRHOM2. The iRHOM2 knockdown-dependent downregulation 
of CK16 could hereby be also shown in both monolayer cells and the organotypic 
culture. Interestingly, knockdown-based changes in the organotypic model mirrored 
the general difference in expression of those proteins in between TOC and normal 
interfollicular skin, thereby implying the validity of the iRHOM2-ADAM17-EGFR axis 
as potential therapeutic target for this kind of hyperproliferative skin disorder. Based 
on these findings ADAM17 and EGFR, as therapeutically relevant targets, were 
blocked in their function by applying specific inhibitors to the TOC model. For the 
inhibition of ADAM17 the small-molecular inhibitor TMI-005 was chosen due to its 
previously published applications as specific and potent inhibitor for ADAM17 
(Thabet and Huizinga 2006; Shu et al. 2011; Maney et al. 2015). In parallel, the FDA-
approved EGFR-inhibitory antibody Cetuximab was used in order to assess the option 
of preventing the increasingly shed EGFR ligands from taking effect by blocking the 
corresponding receptor (Harding and Burtness 2005; Vincenzi et al. 2010). After 
applying both inhibitors to the differentiating organotypics for one week, the 
Cetuximab treatment showed hereby no visible effect on histology or CK16 
expression, even though it had a visible effect when applied in equivalent dosage on 
monolayer (as verified internally by Kelsell group members). 
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One likely explanation for this might be the supply mode via the medium, which 
would require the presumably unlikely upwards diffusion of the comparatively big 
antibody (molecular weight of circa 145 kDa) through the collagen matrix and 
underlying PET membrane. In contrast, the far smaller inhibitor TMI-005 (around 0.4 
kDa) was found to have a visible effect on epidermal thickness, hyperkeratosis and 
CK16 expression. This effect was still relatively subtle though, compared to the 
internal TOC control, and might be increasable through a prolonged treatment 
period.  
Subsequently, a longer treatment was used for a similar application of TMI-005 on 
an organotypic model for Pachyonychia congenita. PC is generally caused by 
mutations in Keratins 6a, 16 or 17, with the patient from which the keratinocytes for 
this model were derived from displaying a dominant mutation in the 1A-helical 
domain of CK16 (Terrinoni et al. 2001). Approaches for the treatment of PC via mTOR-
mediated transcriptional silencing of the affected keratin have already been 
published (Hickerson et al. 2009). Based on the established interaction of the 
iRHOM2-ADAM17 axis with CK16, it was therefore hypothesised that the ADAM17 
inhibitor might have a beneficial effect on the PC organotypic model, in addition to 
the general effect on hyperproliferation (and inflammation) that can be expected 
from the downregulation of ADAM17-mediated TNFD shedding. Consequently, a 
prolonged treatment with TMI-005 did result in a drastic improvement on the 
phenotype of the control PC samples, which did not necessarily reflect a typical 
hyperkeratotic disease phenotype (Leachman et al. 2005) due to the age and quality 
of the used cell line. The concomitant effect on the invasion of cells into the collagen 
gel could hereby also be caused by the inhibitory effect of TMI-005 on matrix 
metalloproteases 1 and 13 , which are known to be involved in the breakdown of 
collagen 1 (Johansson et al. 2000; Hu et al. 2007). In addition to the performed 
Figure 44: Differential protein expression in PC organotypics through inhibitor treatment 
PC organotypics that were cultured in the presence of ADAM17 inhibitor TMI-005 (500nM) for 10 
days show distinct changes in protein expression pattern: inhibitor treatment leads to a complete loss 
of ADAM17 expression and strong reduction in iRHOM2 and Ki67 throughout the organotypic. CK16 
seems slightly down- and Involucrin slightly upregulated. Scale bar represents 50µm. 
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analysis phosphoEGFR-specific antibody staining and ELISA for ADAM17-shedded 
growth factors could be used to further assess the inhibitory effect of applied 
compounds in more detail.  
Overall, the established organotypic keratinocyte culture system could be used in 
first proof-of-principle experiments to model and modulate disease phenotypical 
features to varying degrees for three different inflammatory skin disorders (Table 
14). Further replication and extended analysis (e.g. via Western Blotting in addition 
to the predominantly qualitative IHC readout) have to be done though in order to 
validate these initial results and account for the underlying aspect of batch-to-batch 
variability of in vitro reconstituted tissue models, which is also partially emerging in 
the applied model.          
 
Table 14: Summary of results for in vitro skin disease modelling 
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Cutaneous wound healing is a complicated process dependent on a multitude of 
components from epidermis, dermis, vasculature and immune system (Singer and 
Clark 1999; Baum and Arpey 2005). Modelling it in order to investigate underlying 
mechanisms therefore classically involves in vivo animal studies (Gallucci et al. 2000; 
Galiano et al. 2004), the short-term use of explant skin (Bhora et al. 1995; Xu et al. 
2012) or the breaking down of the multi-layered biological system into simple in vitro 
approximations, such as the widely used monolayer scratch assay (Rodriguez et al. 
2005; Liang et al. 2007). Recently, several approaches have been made to use 
advances in tissue engineering by applying more complex 3D culture systems (El 
Ghalbzouri et al. 2004; Breetveld et al. 2006; Safferling et al. 2013).  Similarly, using 
the already established organotypic culture system, the possibility of a simplified in 
vitro cutaneous wound healing model including epidermal and dermal components 
in a three-dimensional arrangement was investigated, applying three different 
keratinocyte cell lines in order to account for the already demonstrated cell line-
dependent phenotypic variance of normal-phenotype organotypics. The established 
wound protocol was then combined with the TOC model to further recapitulate and 
modulate disease-specific wound healing features. 
 
3.3.2. Establishing an in vitro Epidermal Wound Phenotype 
 
For the process of modelling cutaneous wound healing in vitro, a normal-phenotype 
organotypic based on K17 keratinocytes was cultured for two weeks in order to 
achieve a full differentiation and stratification of the epidermal portion before 
applying a punch wound and culturing it for another two days on an underlying 
collagen layer. After 48 hours of culturing in this arrangement, signs of re-
epithelialisation could be found in the organotypic (Figure 45). Across the full wound 
area (indicated by the absence of the underlying PET membrane which was excised 
as part of the full-thickness wound) keratinocytes were found on top of the wound 
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collagen in a layered and partially stratified arrangement. In addition, 
immunofluorescence staining revealed a distinct expression of marker proteins. The 
differentiation marker CK10, suprabasally expressed in the unaffected parts of the 
organotypic distant to the wound edge, was completely absent from the wound area. 
In contrast, hyperproliferation-associated CK16, proliferation marker Ki67 and the 












Figure 45: Generation of an dermal-epidermal wound model 
Immortalised K17 keratinocytes were seeded unto a primary, dermal fibroblast-containing collagen 1-
scaffold and cultured in airlift condition for two weeks. The by then fully stratified skin equivalent was 
treated with a full thickness 3mm punch wound and transferred on a fresh collagen scaffold to culture 
for an additional two days in airlift. After two days, H&E staining of the full-diameter cross section 
showed signs of ‘re-epithelialisation’ with keratinocytes being present in the wound area in several 
layers. Immunofluorescence staining displayed a wound-specific marker expression, with CK10 being 
absent and, conversely, hyperproliferation and wound specific markers Ki67, CK16 and Cx26 being 
upregulated in the regenerating area. Scale bar represents 100µm.   
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3.3.3. Changes in Wound Phenotype over Time 
 
The progression of the wound-specific features over time was investigated by 
wounding fully differentiated NEB1 organotypics and harvesting them at one, three 
and five days after wounding for comparison (Figure 46). Histological changes 
displayed hereby an advancement of the epidermal portion from the unaffected 
parts of the organotypic unto the wound collagen matrix. One day after wounding a 
short and thinning epithelial tongue was present, while after two additional days the 
whole wound area was covered by a bi-layered epidermal portion which by day 5 
after wounding was further thickened and beginning to stratify. Interestingly, the 
upper layers of the unaffected parts of the organotypic started to detach over time, 
with first signs holes appearing at day 3 after wounding and an almost complete 
detachment after day 5. CK16 upregulation was limited to the wound edge one day 
after wounding and spread first retrograde into the unaffected organotypic and 
subsequently into the wound area over the following days. Similarly, Ki67 expression 
was first increased around the wound edge, which was followed by an even 
upregulation in both directions of the edge. Cx26 on the other hand was strikingly 
upregulated across the wound edge as well as the whole epidermal tongue after the 
first 24 hours and then decreased again over the following four days. 
 
 
3.3.4. Changes in Wound Phenotype in Dependence on Scaffold 
 
In addition to investigating the wound phenotype over time it was further attempted 
to modify wound healing features through environmental manipulation, specifically 
via changes in the wound collagen composition. Using fully differentiated HaCaT-
derived organotypics, several collagen gels (with or without fibroblasts and with the 
optional addition of EGF) were used as underlying wound scaffold to assess the 
potential effect on the wound closure (Figure 47). The collagen gel with any addition 
of cells or growth factors showed hereby minimal progression of the epidermal 
portion into the wound area. The fibroblast-containing wound scaffold was uniformly 
covered by a single layer of keratinocytes whereas the scaffold containing EGF 
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seemed to have caused a strong progression of the epidermal portion into the wound 
area, with a multi-layered and stratified arrangement of keratinocytes advancing 
approximately 300µm past the initial wound edge before thinning into a single layer 
of cells. Correspondingly, the EGF-treated sample displayed a strongly increased 
CK16 staining across the wound edge compared to the other samples which was 
further accompanied by an apparently increased expression of CK10 in the 
suprabasal layers of the wound edge. Combining EGF and fibroblasts seems to negate 
this effect, resulting in a wound healing phenotype very similar in histology and 
marker expression to the sample with only fibroblasts.  
 
 
3.3.5. Wound Model for TOC 
 
The final step in the in vitro modelling of cutaneous wound healing was aimed at 
combining the organotypic wound model with the previously established TOC 
disease phenotype and its manipulation via stable RNA interference (Chapter 3.2.4). 
For this TOC organotypics, with or without shRNA-mediated knockdown for iRHOM2, 
were cultured for two weeks, wounded and then cultured for an additional 24 hours 
on a fibroblast-containing collagen wound scaffold (Figure 48). The control samples 
that were treated with scrambled shRNA displayed constitutive wound healing 
phenotypical features, with CK16 and Cx26 being evenly expressed through even 
unaffected parts of the organotypic and only slight relative upregulation at the 
wound edge. In case of the sh(iRHOM2)-treated samples striking changes in protein 
expression were visible. iRHOM2 was mostly absent in the organotypic, with only 
minimal expression directly at the wound edge. Similarly, CK16 and Cx26 were visibly 
downregulated in the unaffected parts of the organotypic and consequently mostly 
limited in expression to the wound edge. 































3.3.6. Summary and Discussion  
 
Cutaneous wound healing is a complex process and can be negatively impacted by a 
variety of factors, e.g. systemic diseases such as diabetes mellitus can lead to severely 
impaired healing and chronic wounds (Gurtner et al. 2008; Guo and Dipietro 2010) 
or, in contrast, upregulated healing mechanisms can result in hypertrophic scarring 
and the formation of keloids (Robles and Berg 2007; van der Veer et al. 2009). 
Underlying mechanisms are not thoroughly understood and comprehensive models 
can help towards elucidating the causes of dysregulated wound healing and assess 
potential therapeutic approaches (Sherratt and Murray 1990; van den Broek et al. 
2012). While in vivo animal models are the most representative option in terms of 
multi-compartmental complexity, they do come with disadvantages in term of 
species-specific biological variations and general regulatory, logistic and ethical 
aspects in regard to animal experiments (Davidson 1998; Dorsett-Martin 2004; 
Jansen 2004; Nordgren 2004). In vitro models on the other hand tend to still be 
limited in their scope of recreating the full complexity of the native biological system, 
with many epidermal wound models being limited to keratinocyte scratch assays 
(Rodriguez et al. 2005). As a consequence, recent developments were aimed at 
translating advances in the generation of 3D in vitro skin models towards the 
recapitulation of wound healing in a suitable in vitro model (El Ghalbzouri et al. 2004; 
Vaughan et al. 2004; Safferling et al. 2013). 
 
Figure 46: Organotypic wound healing over time 
Fully differentiated NEB1-based organotypics were wounded and cultured for up to an additional 5 
days. Histological stainings of the resulting cross sections reveal hereby a progressive advancing of 
the epidermal keratinocytes unto the wound scaffold, resulting in an increasingly stratified re-
epidermalised layer. This is accompanied by a change in protein expression from the initial wound 
healing marker Cx26 towards the proliferation markers CK16 and Ki67 over time. Scale bar represents 
100µm. 
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Figure 47: Effect of different scaffolds on organotypic wound healing 
Fully-differentiated HaCaT organotypics were wounded and grown for additional 48 hours on scaffolds 
with only collagen (first row), collagen with fibroblasts (second row), collagen with EGF (third row) or 
collagen with fibroblasts and EGF (last row). Histological staining of the cross-sections reveals hereby 
minimal wound closure on the empty scaffold, a keratinocyte monolayer on the fibroblast and 
fibroblast + EGF samples and a strong advancement of the epidermal portion unto the EGF-containing 
scaffold. Furthermore, immunofluorescence staining shows a higher expression of hyperproliferation-
associated CK16 along the wound edge of the EGF-treated sample, followed by a stronger progression 
of differentiation marker CK10 in comparison to the other samples. Scale bar represents 100µm. 
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Employing a similar protocol, slightly adapted to the specifics of the pre-established 
organotypic model, it was now tried to model and modulate epidermal wound 
healing features using immortalised keratinocyte cell lines. The use of a full-thickness 
punch wound, as opposed to for example (superficial) burn or freeze wounds (El 
Ghalbzouri et al. 2004; Breetveld et al. 2006), was hereby chosen for the advantage 
of setting a very clearly defined wound edge (which could later one be traced back in 
cross section stainings via the absence of the easily visible PET membrane in between 
the two collagen layers) and reliably removing all epidermal cells inside the newly 
created wound area. In addition, subsequent wound healing experiments were 
undertaken by using different normal-phenotype keratinocyte cell lines (K17, HaCaT, 
NEB1), in order to assess the adaptability and validity of the experimental setup in 
context of the already established phenotypical variance of the different cell lines 












Figure 48: Modelling and correction of a TOC-specific wound healing phenotype 
Fully differentiated organotypics based on Tylosis keratinocytes, with or without stable knockdown for 
iRHOM2, were wounded and cultured for additional 48 hours. Non-knockdown samples display an 
expression of hyperproliferation (CK16) and wound healing (Cx26) markers throughout even the 
unwounded parts of the organotypic (left side of each picture), whereas the knockdown of iRHOM2 
leads to a restriction of expression to the actual wound edge (right side of each picture). Scale bar 
represents 100µm. 
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A first application of the protocol in organotypics using the K17 cell line did 
consequently result in a clear display of wound healing features. A newly present 
multi-layer arrangement of keratinocytes on top of the wound collagen scaffold was 
the likely result of re-epithelisation involving probably migration and certainly 
proliferation of keratinocytes along the wound edge. This was further supported by 
protein marker expression patterns typical for cutaneous wound healing. Keratin-
reorganisation plays an important role in the re-epithelisation after acute skin injury 
and especially Keratin 16, and its type 2 binding partner Keratin 6a, are described as 
essential component in this process (Brody 1988; Paladini et al. 1996; Wojcik et al. 
2000; Safer et al. 2004). The concomitant downregulation of differentiation-
associated Keratin 10 is hereby further indication for an actual remodelling of 
keratins in the organotypic wound and accompanying de-differentiation and 
proliferation of wound edge keratinocytes, which is also apparent through the 
increased Ki67 expression in the wound area (Betz et al. 1993; Safferling et al. 2013). 
Interestingly, overly abundant expression of Ki67 inside the epithelial tongue has 
previously also been associated with chronic ulcerous wound healing, which could in 
this case be connected to the use of immortalised, hyperproliferative keratinocytes 
(Usui et al. 2008).  Connexin 26 is a wound-specific gap junction protein and is 
thought to be especially expressed by hyperproliferative keratinocytes in the leading 
edge of spontaneous wounds (Kretz et al. 2003; Brandner et al. 2004). The expression 
of it in the wound area and especially at the actual wound edge of the organotypic 
can therefore be seen as further validation of the in vitro-generated wound healing 
features. Additional gap junctions could be stained for though to further confirm the 
phenotype, e.g. Connexin 30 which is expressed together with Connexin 26 or 
Connexin 43 which is constitutively expressed in healthy epidermis and subsequently 
downregulated during wound healing (Coutinho 2003; Becker et al. 2012). 
After verifying a general wound phenotype in the model, the next step involved a 
time-dependent investigation of phenotypical features in order to assess re-
epithelisation and changes in protein expression over a timeframe of up to five days 
after wounding. Histology stainings could hereby indeed show the advancing of an 
epidermal tongue from the wound edge unto the collagen scaffold of the wound 
area, followed by proliferation-based layering of keratinocytes and the onset of 
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stratification into a horizontally flattened upper layer. A re-emergence of 
differentiation markers such as Keratin 10 or Involucrin in the re-epithelised parts 
could not be detected though (data not shown), which might be due to the limited 
time frame of the model not allowing for later-stage differentiation of the newly 
formed epidermal portion. Corresponding to the expansion of the epithelial tongue, 
proliferation markers CK16 and Ki67 were shown to spread in upregulation from the 
initial wound edge and along the leading edge into the re-epithelised wound area. 
The additional retrograde increase for both of the markers into the unaffected parts 
of the organotypic past the wound edge was hereby similar to the retrograde 
spreading of wound healing markers described before and is likely attributed to 
increased cytokine and growth factor secretion at the wound edge affecting those 
parts of the epidermal portion (Brandner et al. 2004). Contrasting the temporal 
pattern of the proliferation markers, Connexin 26 was found to be maximally 
expressed at the wound edge early on and subsequently downregulated again over 
the following days. This generally corresponds with earlier findings in skin (Brandner 
et al. 2004), although the process seems to be accelerated in comparison which 
might be a consequence of the general hyperproliferation-phenotype and 
subsequently higher turn-over of the organotypic cell culture. In this regard, the 
changes over time in the non-wounded parts of the organotypic are of interest as 
well. The apparent disintegration and subsequent separation of the upper suprabasal 
layers of the epidermal portion has not be seen in previous experiments and might 
be connected to the overall prolonged culture time of the organotypic (up to 19 days 
instead of 14) which might possibly allow the continuously proliferative epidermal 
portion to grow to a degree where the upper layers can no longer be sufficiently 
supplied with nutrients from the basal medium reservoir. This essential nutrient 
diffusion might also be hampered by the additional layers of the wound model and 
it is furthermore feasible to assume that the existing hyperproliferation might be 
increased by the already described retrograde wound effect and therefore enhances 
this problem in addition to the prolonged culture time.  
One important aspect in the setup of the wound models was its modular nature, 
achieved through the separate preparation / pre-culture of the organotypic and 
wound scaffold. This allows for an easy combinatorial approach in regard to different 
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conditions, for example the composition of the collagen mixture that comprises the 
wound scaffold. Subsequently, it was tested if the addition or omission of different 
components in the dermal equivalent would have an effect on the epidermal wound 
healing features. Dermal fibroblasts are shown to have a strong paracrine effect on 
proliferation and migration of epidermal keratinocytes, which is even more 
enhanced in an acute wound healing setting, through the secretion of several 
interleukins and growth factors (Werner et al. 2007). It is therefore a feasible 
assumption that a cell-free collagen scaffold would result in a reduced 
epithelialisation in the model. This hypothesis seemed to be verified by the 
experimental findings which showed a stunted advancement of the epidermal 
portion unto the fibroblast-free scaffold. Interestingly, this was accompanied by an 
apparent absence of CK10-reduction which might imply a delayed de-differentiation 
of the wound edge keratinocytes, possibly due to the absence of keratinocyte growth 
factor (KGF) which can be secreted by dermal fibroblasts and has been described to 
have a potentially beneficial effect on keratinocyte re-differentiation (Staiano-Coico 
et al. 1993; Werner et al. 1994). Similarly, epidermal growth factor is known for its 
supportive effect on wound healing, primarily via the upregulation of migration and 
proliferation of wound edge keratinocytes (Nanney and King 1988; Bodnar 2013; 
Kuroyanagi et al. 2014).  Correspondingly, an EGF-supplemented wound scaffold 
seemed to have a strikingly positive effect on wound closure in the organotypic 
model, as has already been shown before for different full-thickness wound models 
(El Ghalbzouri et al. 2004). A visible upregulation of CK16 in keratinocytes along the 
leading edge further supports the assumption that this is actually a direct result of 
the EGF treatment, since the growth factor is known to upregulate CK16 expression 
(Jiang et al. 1993; Wang and Chang 2003). Upregulation of CK10 via EGF on the other 
hand has not been described so far, the visible increase in expression might therefore 
be more indicative of a generally more advanced wound healing and subsequent 
maturation of the re-epithelised areas. Combining EGF-treatment with the presence 
of fibroblasts in the wound scaffold seems to mostly negate the EGF-derived effect 
and results in a phenotype similar to the fibroblasts-only sample. Fibroblasts are 
known to express EGF receptors and to furthermore exhibit a reduced 
responsiveness to EGF stimulation with age (Shiraha et al. 2000; Cao et al. 2006; 
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Simpson et al. 2010), the ineffectual binding of EGF to the embedded (high-passage) 
fibroblasts might therefore be a likely explanation for this observation. Overall 
though, the modulation of the underlying the wound scaffold in order to influence 
the epidermal wound healing phenotype has been verified to be a viable option, 
which opens up a variety of possibilities to advance the wound model into a more in 
vivo-like setting. Two examples would be the addition of a simple capillary system by 
incorporating HUVEC endothelial or even adipose-derived stem cells in the collagen 
scaffold before adding it to the wound model (Black et al. 1998; Auxenfans et al. 
2012) or the inclusion of an immune system component through the embedding of 
macrophages or even tissue-resident T cells (Bechetoille et al. 2011; Linde et al. 2012; 
Van Den Bogaard et al. 2014). An even simpler method would be the alteration of 
the scaffold composition itself by replacing collagen 1 with a defined mixture of 
collagen 3, fibronectin and hyaluronan in order to mimic early stage granulation 
tissue (Häkkinen et al. 2011). In addition to making the wound model more in vivo-
like in general, dermal components could also be used to model more aberrant 
healing mechanisms, for example by recapitulating hypertrophic scarring through 
the application of disease-specific fibroblasts (van den Broek et al. 2012, 2014). 
The combination with a previously established disease phenotype was a logical next 
step in the establishment of the organotypic wound model, since epidermal 
disorders can influence acute wound healing, for example through alteration of 
cytokine secretion and alteration of signalling pathways (Werner et al. 2007; Guo and 
Dipietro 2010). TOC is hereby an interesting candidate due to the specific, EGFR-
based constitutive wound healing phenotype (Brooke et al. 2014; Ellis et al. 2015).  
Consequently, untreated control TOC organotypics displayed an expression of CK16 
and Cx26 throughout even the unaffected parts of the parts of the epidermal portion, 
far beyond the wound edge. Employing the partial shRNA-mediated knockdown of 
iRHOM2, which has already been described to downregulate wound healing features 
such as proliferation and migration in monolayer cultures (Chapter 3.2.4), could 
subsequently be restricted to the area close to the wound edge and by that normalise 
the wound healing phenotype in the TOC model. In conclusion, this proof-of-principle 
experiment demonstrates the valid option of using the model to recapitulate 
disease-specific wound healing features and the subsequent effect of potential 
Results: Wound Model 
 118 
therapeutic strategies on those. Building up on these findings, it would now be 
interesting to test the possibility of using external stimuli to achieve similar effects, 
for example through the application small-molecular compounds directly into the 
wound area (Galiano et al. 2004). 
Overall, the principle of using the organotypic culture system in order to simulate 
cutaneous wound healing could be shown to be viable for a variety of normal- and 
disease-phenotype keratinocyte cell lines, even though continuous optimisation can 
and has to be undertaken. Practical aspects, such as the right method of tissue 
processing in order to avoid processing artefacts especially along the more fragile 
wound edge, or optimisation of the culture protocol are an important factor to 
consider for future development. Adding to the complexity of the model is another 
option that could be followed up. So far, only epidermal and dermal components are 
included but it is feasible to assume that the incorporation of vascularisation and 
inflammation, both vital components in the case of in vivo wound healing (Singer and 
Clark 1999; Gurtner et al. 2008), could be achieved through relatively easy means. 
Another interesting alternative would be the introduction of bacterial cultures to the 
wound model in order to investigate the interplay of microbiota and cutaneous 
wound healing (Edwards and Harding 2004; Scales and Huffnagle 2013). For example, 
a suitable pathogen for this would be Staphylococcus aureus, which is a common skin 
pathogen and has been shown to have a negative effect on wound healing (Haisma 
et al. 2014; Popov et al. 2014).  
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In parallel to using the organotypic keratinocyte culture system to model disease 
phenotypes and investigate potential therapeutic targets, another intended 
application was the assessment of nanopolymer-based topical delivery approaches. 
Any external application of a formulation on the skin has to take into account the 
native permeability barrier function of the upper epidermal layers, which can be 
crossed through several mechanisms / pathways in order to deliver the drug to the 
intended area of effect (Prausnitz et al. 2004; Cevc and Vierl 2010). Providing a 
suitable (and scalable) model of the epidermal permeability barrier would therefore 
be a distinct advantage in the early development stages of any skin delivery system, 
providing the means of assessing and optimising the application of the formulation 
in vitro (Jepps et al. 2013; Mathes et al. 2014; Flaten et al. 2015) before proceeding 
into more complex and elaborate systems such as animal models (GODIN and 
TOUITOU 2007).Thermo-responsive, PolyNIPAm-based nanogels have recently 
become a focus of ongoing research since their unique chemical properties make 
them interesting candidates for controlled drug delivery (Bhuchar et al. 2012; 
Bergueiro and Calderõn 2015). Shrinking in volume and consequently expelling their 
cargo at a threshold temperature around 35°C, these nanopolymers would be ideal 
for the controlled release of compounds into the lower layers of the epidermis after 
topical application (Samah et al. 2010; Singka et al. 2010; Witting et al. 2015).  
Subsequently, fluorescently labelled PolyNIPAm-based nanopolymers were obtained 
from Prof Marina Resmini (School of Biological and Chemical Sciences, QMUL) and 
applied on the organotypic model (in comparison to explant skin) after assessing 
their general interaction with epidermal keratinocytes in monolayer cultures. After 
verifying the successful epidermal localisation of the nanopolymers as a result of 
optimised application protocols, the actual delivery and release of a model drug (FFA) 
into the artificial tissue was analysed.   
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3.4.2. Nanopolymer Internalisation in Keratinocytes and Effect on Viability 
 
Negatively and neutrally charged nanopolymers were incubated in various 
concentrations on K17 keratinocytes for 24 and 48 hours before being assessed in 
regard to their cell internalisation and effect on cell viability (Figure 49). The 
negatively charged polymers displayed hereby a concentration-dependent increase 
in internalisation, visible through cytoplasmic green fluorescent signal and the 
appearance of cytoplasmic vesicles, which further increased with additional 
incubation time. In contrast, the neutrally charged nanopolymers showed only 
minimal signs of internalisation but instead formed floating, spherical aggregates 
which again were dependent in their size on concentration and incubation time. 
Correspondingly, fluorescent readouts for the Alamar Blue viability assay display only 
a slight decrease with higher concentrations after 48 hours in case of the neutrally 
charged polymers. The negatively charged nanopolymers on the other hand resulted 
in a mostly linear decrease with higher concentrations, with overall higher 
fluorescence levels (due to an increase in cell number) and a steeper decline after an 
additional 24 hours, resulting in an almost 50% decrease in viability for the highest 
concentration of 1 mg/ml in comparison to the untreated control. 
In-depth analysis of the internalised negatively charged nanopolymers was 
subsequently done by incubating at the highest concentration (1mg/ml) for 24 / 48 
hours and correlating the internalised green polymer signal with subcellular 
compartments stained via ICC in red, resulting in a colocalisation of the polymer 
signal with markers for cis-Golgi (GM130), trans-Golgi (TGN46) and endolysosomes 
(LAMP2). In order to gain more detailed information about the nanopolymer 
internalisation, image analysis was performed on the colocalisation pictures and the 
correlation of green and red signal quantified and compared (Figure 50). The general 
correlation coefficients PsCo and Li’s ICQ display hereby a similar trend as the 
Manders 1 coefficient which denotes the colocalising fraction of green pixels: a 
comparatively large decrease for GM130 in between 24 and 48 hours with a 
moderate decrease for LAMP2 and a relatively slight one in case of TGN46. The red 
signal-specific Manders 2 coefficient displays a different pattern with slight increases 
for GM130 and LAMP2 and a minimal decrease for TGN46.  







Results: Nanopolymer Application 
 122 
 
3.4.3. Topical Application of Nanopolymers on Skin and Organotypics 
 
Subsequent to assessing the interaction of the nanopolymers with keratinocytes in 
monolayer cultures, polymer solutions were topically applied to explant skin and K17 
normal-phenotype organotypics. The aim in this was the investigation of a possible 
penetration of the nanopolymers across the permeability barrier in the upper 
epidermal layers and subsequent localisation in the epidermis. Consequently, cross 
sections of treated skin and organotypic samples were checked for the presence of 
green fluorescent nanopolymer signals (Figure 51). Correlating the green 
fluorescence with the brightfield image, and a nuclear counterstain later on for 
better contrast and resolution, it became apparent that the polymers predominantly 
stayed on top of the stratum corneum of the skin or the equivalent uppermost layer 
of the organotypic respectively. Another observation was the strong, inherent 
autofluorescence of the dermal parts of the explant skin, visible in both the treated 
as well as the control samples. In consequence to the initially unsuccessful topical 
application of the negatively charged nanopolymers a more advanced attempt was 
undertaken, employing both the negatively and neutrally charged polymers in 
conjunction with two chemical penetration enhancers (DMSO or BA) and using 
quantitative image analysis for generating an easily comparable readout (Figure 52). 
Figure 49: Internalisation of nanopolymers in keratinocytes and effect on viability 
Negatively and neutrally charged nanopolymers were added to pre-cultured monolayer keratinocytes 
in concentrations ranging from 0 to 1 mg/ml and incubated together for 24 hours (a) and 48 hours (b). 
Negatively charged nanopolymers internalise into the cells in a concentration- and time-dependant 
manner, visible through cytoplasmic green polymer signals and the appearance of internalisation-
associated vesicles inside the cells. Neutrally charged nanopolymers only show minimal internalisation 
but instead tend to form aggregates, visible as yellow floating spheres the diameter of which seems 
to be concentration and time-dependant as well. Correspondingly to the internalisation data an 
Alamar Blue assay verified a negative effect of nanopolymers on cell viability which increased with 
time and concentration and is not visible for neutrally charged nanopolymers. 
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Looking at the localisation of both types of polymers in the epidermal area of interest 
of explant skin samples (Figure 52 a), it was found that in case of the negatively 
charged polymer both enhancers resulted in an increased epidermal localisation, 
with a slightly stronger effect for BA. The neutrally charged nanopolymers on the 
other hand seemed to display a slightly higher localisation on their own, which 
decreased in combination with BA and increased with DMSO, but was generally more 
variable, evident through higher error bars. Replicating the application of the 
negatively charged polymers on normal-phenotype organotypics resulted in similar 
results to the skin application (Figure 52 b). Even though overall levels of localisation 
were lower than in the skin the enhancer-dependent increase followed similar a 
pattern. Correspondingly, when comparing the enhancer-induced fold change in 
localisation in between skin and organotypic application (Figure 52 c), the results 
were very comparable (with the organotypic application displaying slightly lower 
error bars). 
After assessing the potential of the negatively charged nanopolymers to cross the 
epidermal permeability barrier, the next step involved their application as delivery 
system for the model drug FFA. For this, FFA-loaded polymers were topically applied 
on organotypics under various conditions, the released FFA extracted from the 
treated tissue and measured via HPLC (Figure 53).  
 
Figure 50: Colocalisation of nanopolymers with subcellular compartments 
Image stacks for nanopolymer-subcellular compartment co-stainings (sample images shown in (a) 
with the compartments in red and nanopolymers in green) were quantified through using to general 
co-localisation coefficients with PsCo and Li’s ICQ as well as channel-specific Manders coefficients, 
with Manders 1 indicating the fraction of colocalising green nanopolymer signals and Manders 2 
showing the fraction of colocalising red department signals. Absolute values for each time point (b) 
were put into relation to display the relative changes over 24 hours (c). Pearson, Li’s ICQ and Manders 
1 show hereby similar changes with a strong decrease in colocalisation for GM130 (cis-Golgi), 
moderate decrease for LAMP2 (endolysosome) and comparatively slight decrease in the case of 
TGN46 (trans-Golgi). Nanopolymer-based Manders 2 displays a different trend with only a slight 
decrease in TGN46 and actual increases in colocalisation for GM130 and LAMP2.  
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Figure 51: Visualisation of topically applied nanopolymers on skin and organotypic 
Green fluorescent nanopolymers were topically applied on explant skin and normal-phenotype 
organotypics for 24 hours and their retention in the uppermost layers initially visualised in the context 
of brightfield images (a). Later on, DRAQ5 nuclear counterstaining and high-resolution confocal 
imaging were used to confirm these findings (b). Scale bar represents 25µm. 
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Using a commercially available FFA formulation as gold standard, FFA release into 
the organotypic tissue could be seen to increase slightly over time and more 
pronounced with an increase in temperature.  
A similar trend could be detected for the nanopolymer applications (without the 
addition of penetration enhancer), albeit with some differences. While the FFA 
release a room temperature is comparable to the commercial formulation for both 
time points, the increase at 35°C was strikingly delayed and far more pronounced 
with almost 25% more recovered FFA after 24 hours than at 12 hours, slightly 
surpassing the release value for the gold standard at this point. The combination of 
the FFA-loaded nanopolymers with BA appeared to result in a slight decrease in 
recovered FFA over time, for both the RT-incubated samples as well as the samples 
at 35°C which displayed generally higher FFA release rates in comparison. Overall, 
the three different formulations showed similar release levels at RT, with no major 
difference in between 12 and 24 hours, and distinctly different changes over time at 
35°C, with a slight decrease for the BA-combined polymer sample, a slight increase 
for the commercial formulation and a drastic increase for the pure nanopolymers.      
 
 
3.4.4. Summary and Discussion 
 
Due to progressively more restrictive legislation and waning public acceptance, there 
is an increasing need for the pharmaceutical and especially cosmetic industry to 
move away from the use of animal models and adopt suitable in vitro assays for early 
development stages of new drugs and delivery systems (Mathes et al. 2014). 
Complex organotypic in vitro assays have to fulfil several requirements in order to be 
able to sufficiently replace in vivo animal experiments (Flaten et al. 2015): besides 
scalability and reproducibility, which are of importance for large-scale testing series, 
the faithful modelling of biological parameters in the in vitro system is a crucial factor 
for the viability of any given model (Lotte et al. 2002; Götz et al. 2012a, 2012b). In 
regard to skin models for the assessment of (trans-)dermal compound applications 
the presence of a properly functioning permeability barrier is consequently essential 
(Thakoersing et al. 2012; Andrews et al. 2013; Jepps et al. 2013).  The barrier function 
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of the fully differentiated, normal-phenotype organotypics has already been 
demonstrated by using a Lucifer Yellow permeation assay (Chapter 3.1.3) but a more 
thorough follow-up assessment of therapeutically relevant applications in 
comparison with explant skin was still to be undertaken. For this, thermo-responsive 
poly-NIPAm-based nanogels were used since their conformational properties makes 
them ideal candidates for targeted drug carriers (Bhuchar et al. 2012; Bergueiro and 
Calderõn 2015).  
In initial preparation of the actual application, the basic interaction of the 
nanopolymers with keratinocytes was tested in monolayer cultures. Since surface 
charge is known to influence skin penetration and cellular uptake of particles, 
neutrally and negatively charged polymers were therefore tested in parallel (Cho et 
al. 2009; Gillet et al. 2011; Yang et al. 2012). Positively charged polymers were hereby 
already dismissed in earlier stages of chemical characterisation due to unfavourable 
release characteristics. It has been shown that negatively charged polymers 
internalise to a higher degree than neutrally charged ones but less than particles with 
a positive charge, which is likely connected to the overall negative charge of the 
plasma membrane (Jiang et al. 2011; Fröhlich 2012; Kralj et al. 2012). The same trend 
could be seen in the internalisation experiment, though further enhanced by the 
unique property of the neutrally charged polymers to form inert aggregates, possibly 
due to hydrophobic interactions in the aqueous solution. In contrast, the negatively 
charged polymers readily internalised into the keratinocytes and showed only 
moderately negative effects on the viability of the cells at the applied concentration 
range. Viability was hereby measured via an Alamar Blue assay, which has been 
widely published in the assessment of potentially toxic compounds and is based on 
the reducing conditions in the cytoplasm of living cells (Rampersad 2012). 
Subsequently, this initial viability measurement could be complimented by more 
detailed assessments of plasma membrane integrity , cell proliferation or essential 
cellular components such as mitochondria, all of which are described as potential 
mediators of nanopolymer-mediated cytotoxicity (Marquis et al. 2009; Fröhlich 
2012).  
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In conclusion to the general verification of negative polymers internalising into 
keratinocytes, a more detailed look at internalised polymers in relation to subcellular 
compartments was undertaken. A first finding was hereby that the polymers 
appeared to co-localise with components of the endolysosomal pathway, namely 
late endolysosomes marked by LAMP2 (Winchester 2001; Eskelinen 2006). This 
seems to indicate an active vesicular uptake of the polymers via endocytosis as 
opposed to passive plasma membrane penetrance, which seems to be a rare 
internalisation route mostly connected to cationic gold particles (Lin et al. 2010; 
Taylor et al. 2010). Correspondingly, clathrin-dependent endocytosis has already 
been described as possible internalisation route for a variety of negatively charged 
nanoparticles (Rejman et al. 2004; Jiang et al. 2011; Zaki et al. 2011). Alternatively, 
other evidence suggests a clathrin-independent endocytosis for small-enough 
anionic particles, which would be the case for the 10nm-wide negatively charged 
polymer, outside the endolysosomal pathway (Harush-Frenkel et al. 2007; LAI et al. 
2007). To which degree this specific nanopolymer is dependent on clathrin-mediated 
endocytosis could consequently be clarified with relative ease though by blocking 
assembly of the clathrin complex through compound treatment or RNA interference 
(Huang et al. 2004; Gratton et al. 2008).  Other compartments found to co-localise 
with internalised polymers were the cis- and trans-Golgi, which would point to an  
 
Figure 52: Quantification of epidermal nanopolymer localisation in skin and organotypic 
Green-fluorescent nanopolymers (both with negative or neutral surface charge) were topically applied 
for 24 hours on explant skin, alternatively in conjunction with DMSO or BA as penetration enhancer, 
and the resulting sample sections analysed for epidermal localisation of the nanopolymers (a). The 
negatively charged polymers show hereby a strongly increased localisation in the epidermal area of 
interest with BA and a slightly less increased localisation with DMSO. The neutrally charged polymers 
show a decrease in localisation with BA and strong increase with DMSO. Parallel application of the 
negatively charged nanopolymers on normal-phenotype organotypics results in a similar, though 
generally lower-levelled, pattern as in skin (b). Normalising the values to the pure polymer application 
reveals very similar enhancer-dependant changes of localisation in both skin and organotypic areas of 
interest (c). 
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alternative intracellular transport route from the endosomal compartment 
retrograde via the trans-Golgi towards cis-Golgi and possibly also ER, potentially 
followed by subsequent exocytosis (Jiang et al. 2010; Sahay et al. 2010; Kafshgari et 
al. 2015). Interestingly, GM130-staining for the cis-Golgi seemed to show signs of 
structural disintegration of the cis-Golgi apparatus, possibly due to enrichment of the 
polymers followed by a concentration-driven cytoplasmic escape and concomitant 
disruption of the Golgi cisterns (Domozych 1999; Bantel-schaal et al. 2002; Strobel et 
al. 2015). Overall the Manders 2 coefficient, which illustrates the involvement of the 
respectively stained compartment, seemed to indicate an accumulation of the 
polymers in both the endolysosomal and cis-Golgi compartments whereas the trans-
Golgi displayed a slight decrease in polymer co-localisation. This could be explained 
by the trans-Golgi’s role as an intermediate compartment which does not retain 
polymers but transports them either further towards the ER or alternatively unto an 
exocytotic route via exosome vesicles (Sakhtianchi et al. 2013; Kafshgari et al. 2015; 
Strobel et al. 2015). This would also correspond with the comparatively mild changes 
in Manders 1 and Pearson coefficient as well as Li’s ICQ for TGN46, even though 
changes in these three parameters are mostly driven by the cytoplasmic enrichment 
of the green-fluorescent polymers, which does not apply to Manders 2, and therefore 
less reliable in this specific case. 
After verifying a typical internalisation pattern and acceptable degree of cytotoxicity 
for the chosen nanopolymers they were subsequently taken forward to a topical 
application on explant skin and organotypics, similar in execution and analysis to 
experiments undertaken before by other groups (Alnasif et al. 2014; Witting et al. 
Figure 53: Quantification of nanopolymer-mediated delivery of FFA in organotypics 
FFA-loaded nanopolymers, as well as a commercial FFA formulation as gold standard, were topically 
applied on normal-phenotype organotypics for up to 24 hours at RT and 35°C. Subsequently, the FFA 
that was released inside the organotypics was retrieved, quantitated via HPLC and related to the 
initially loaded amount. The commercial formulation shows hereby a steady increase in recovered FFA 
over time and with higher temperature. Nanopolymer-loaded samples only show a slight increase in 
released FFA after an additional 12 hours or at 35°C but a drastic rise after 24 hours at the higher 
temperature. The combination of nanopolymers and BA seems to lead to slightly higher release of FFA 
at higher temperature but an overall decrease of retrievable FFA after 24 hours. 
 
Results: Nanopolymer Application 
 132 
2015). For the topical application the highest used concentration from the monolayer 
experiments (1 mg/ml) was chosen after initial results showed a strong retention of 
polymers in the uppermost layers of the skin and organotypics. The rational was 
hereby that even though the polymer concentration in the topically applied solution 
resulted in moderate toxicity and possibly detrimental effects on intracellular 
compartments, the actual concentration in the tissue would be considerably lower 
due to the limited penetrance and therefore in a range with no negative effect on 
the surrounding keratinocytes. Furthermore, since penetrance of the nanopolymers 
by themselves was negligible the two FDA-approved penetration enhancers DMSO 
and Benzylic alcohol were added to the polymer solutions in subsequent experiments 
(Sand et al. 2007; Marren 2011).  
Consequently, both negatively and neutrally charged polymers showed distinct 
changes in the application on explant skin with or without the penetration 
enhancers. The neutral polymers seemed to penetrate slightly better on their own 
but were generally very variable, even more so than the negatively charged ones, 
and showed a tendentially reduced penetration with BA, which would imply 
unfavourable interactions of the neutral polymer with the alcohol. These findings in 
combination with the results of the monolayer experiments led to the 
discontinuation of the neutral polymer for further applications. In contrast, the 
negatively charged polymers displayed a promising pattern of enhanced penetration 
with slightly less variations and were therefore subsequently applied to the normal-
phenotype organotypics as well, resulting in a very similar enhancer-dependent 
pattern albeit with lower variation in between samples. 
Results of the penetration assessments based on image analysis have to be regarded 
in relation to the inherent limitations of the system. Dermal autofluorescence around 
the same wavelength as the polymer emission and the inability to account for 
polymers that might have penetrated all throughout the organotypic sample limit 
the assessment to the localisation of polymers inside the epidermal portion. As a 
consequence, it is impossible to tell how much the different results for various 
enhanced polymer solutions are due to over-penetration of polymers across the 
epidermis and into non-detectable areas of the tissue. This might be sufficient for 
carrier systems aimed at the delivery of compounds to epidermal keratinocytes, 
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which would for example be the case for inflammatory skin diseases, but does not 
account for the possibility of assessing transdermal delivery of systemically active 
drugs. Furthermore, even for locally active compounds the information of systemic 
entry is of importance in regard to pharmacokinetic and toxicological studies (Shah 
et al. 2014). The existing model would therefore have to be expanded by the addition 
of a Franz diffusion cell, which would make it possible to detect the fraction of 
polymers that diffuse through and out of the (organotypic) tissue and thereby 
complete the assessment (Samah et al. 2010; Witting et al. 2015). Nonetheless, the 
strikingly similar, though limited, readout for both the application on explant skin as 
well as organotypic seems to verify the possibility of recreating a functionally 
equivalent permeability barrier function in the model which has been described as a 
critical and mostly lacking point in the development of organotypic skin models 
before, especially when based on immortalised keratinocyte lines (Petrova et al. 
2014).     
In conclusion to ascertaining the possibility of re-creating a functional permeability 
barrier in the normal-phenotype organotypic, the model was then taken one step 
further towards a therapeutically relevant application by assessing the actual drug 
release from topically applied nanopolymers. For this proof-of-principle experiment, 
flufenamic acid (FFA) was chosen as a model drug which has already been used in 
this context by various groups (Luengo et al. 2006; Santander-Ortega et al. 2010). 
Negatively charged, FFA-loaded polymers were therefore applied to the organotypic 
model with or without the addition of BA as penetration enhancer and compared to 
equivalent dose of a commercially available FFA-containing gel formulation 
(Mobilisin£) as gold standard. In order to achieve a more sensitive, quantifiable 
readout HPLC analysis was hereby performed on extracts from whole tissue lysates 
by the School for Biological and Chemical Sciences at Queen Mary University London. 
The resulting preliminary data seems to indicate a temperature-dependent increase 
in drug release over time with the nanopolymers, which would correspond with their 
thermo-responsive properties, and generally similar levels of tissue-released FFA for 
the polymer- and formulation-treated samples. A slight decrease in recovered FFA 
over time for the BA-containing sample might again be based on an over-enhanced 
penetration of polymers and compound through the organotypic into the underlying 
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culture dish. Overall though, repeated experiments would have to be done in order 
to account for inherent variability of the model and application and validate the 
observed preliminary differences. Furthermore, the actual mode of action for the 
release of FFA from the polymers into the organotypic tissue would have to be 
studied in more detail in order be able to differentiate between for example an 
intracellular release of the drug by phagocytosed polymers versus the possibility of 
polymers being retained in the upper epidermal layers and acting as reservoirs for a 
sustained extracellular release of compounds and subsequent cellular uptake 
(Witting et al. 2015). The combination of different fluorophores, one covalently 
linked to the polymers and one loaded as releasable cargo, and higher-resolution 
imaging should hereby be suitable to provide more information in this regard 
(Pappinen et al. 2012).   
After performing a series of preliminary experiments in order to investigate the 
potential of applying the organotypic culture model for the assessment of topical 
drug delivery the results appear promising but in need of further optimisation. It was 
possible to generate an epidermal barrier function that displays skin-similar 
characteristic changes in polymer permeation in reaction to different conditions but 
in order to account for the penetration of topically applied substances throughout 
the organotypic further enhancements, for example in form of a Franz cell system, 
have to be made. In addition to the possibility of a systemic entry of the drug via 
dermal capillaries, another important aspect of skin drug delivery is the interaction 
of compounds and carriers with dermally located parts of the immune system; the 
incorporation of macrophages and other tissue-resident lymphocytes would 
therefore be a distinct advantage for the overall viability of the model (Bechetoille et 
al. 2011; Linde et al. 2012; Van Den Bogaard et al. 2014). Since skin appendages 
present an important route for the (trans-)dermal delivery of drug, it would 
furthermore be an intriguing option to include pre-cultured or artificially generated 
sweat glands or hair follicles into the organotypic (Michel et al. 1999; Huang et al. 
2010, 2012; Lindner et al. 2011). Subsequent to optimising the normal-phenotype 
model for the assessment of topical delivery it would also be interesting to then 
perform the same assessment in the established disease phenotypes (Chapter 3.2), 
since both HI and TOC are known to manifest in barrier dysregulation (Thomas et al. 
Results: Nanopolymer Application 
 135 
2009; Brooke et al. 2014). Additionally, the delivery of already tested compounds, for 
example the ADAM17-inhibitor TMI-005 for TOC, would allow for a simple and 
therapeutically relevant readout for the successful application, similarly to an already 
published delivery of TGM-1 to disease organotypics and the subsequent alleviation 
of the specific phenotype (Witting et al. 2015). In parallel to the disease models, the 
organotypic wound model (Chapter 3.3.) also presents an interesting opportunity for 
the application and assessment of several nanomaterials which have already been 
described in their positive effect on epidermal wound healing (Leu et al. 2012; Rigo 









4. Final Discussion 
 
4.1. Summary of the Results 
 
The overall aim of this thesis project was the establishment of a modifiable 
organotypic keratinocyte culture system and its application in modelling of 
cutaneous disease phenotypes and epidermal wound healing as well as the 
assessment of topical drug delivery via nanopolymeric carrier systems. 
 
A collagen-based organotypic cell culture protocol was established and used to 
generate skin equivalents for a variety of immortalised cell lines (HaCaT, nTERT, K17, 
NEB1). While very variable and with a more or less pronounced tendency towards 
hyperproliferation (dependent on the individual cell line), all of them resulted in skin-
like phenotypes, showing mostly appropriate protein expression patterns and 
epidermal barrier function (which further included a stratum corneum-like 
uppermost layer, visible in histological stainings). 
 
The culture system was then expanded to include several disease models based on 
patient-derived keratinocyte cell lines for Harlequin ichthyosis, Tylosis and 
Pachyonychia congenita. The HI model, possessing a recessive loss-of-function 
mutation in the ABCA12 gene, displayed various disease-specific phenotypical 
features in regard to histology (hyper- and parakeratosis) and protein expression 
(upregulation of CK16 and Involucrin). Other features, such as an expected absence 
of non-polar lipids, were not present, which might be explained by the extended 
culture time of the immortalised cells and a connected self-improvement 
mechanism. Nonetheless, in an attempt to alleviate the presented disease features 
two agonistic compounds for LXR and PPARG were applied to the model, resulting in 
the intended upregulation of ABCA1 and consequently a slight improvement in 
regard to the histological features and Involucrin expression. The TOC model showed 
a hyperproliferation phenotype, corresponding to the disease-causing gain-of-
function mutation in iRHOM2 and the resulting ADAM17-dependent upregulation of 
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EGFR signalling, which manifested itself in a thickened, disordered epidermal portion 
and upregulated expression of iRHOM2, CK16 and EGFR. Epidermal thickening and 
CK16 overexpression were subsequently counteracted via two independent 
approaches: shRNA-mediated (partial) knockdown of iRHOM2 and application of the 
ADAM17 inhibitor TMI-005. The successful application of TMI-005 was consequently 
extended to the PC model, on the basis of the general anti-hyperproliferative effect 
of TMI-005 and the demonstrated functional connection between CK16, which 
harbours the PC-causing gain-of-function mutation, and the iRHOM2-ADAM17-EGFR 
axis. Using the ADAM17 inhibitor in the PC model resulted in comparable results to 
the one from the TOC model: hyperproliferation-associated markers were slightly 
down- and differentiation marker slightly upregulated, in addition to an 
improvement to the initially disordered histology. 
 
In parallel to the various disease phenotypes, a full-thickness dermal-epidermal 
wound healing model was established. Showing a progressive re-epithelialisation and 
spatially appropriate expression of wound healing markers such as CK16 and Cx26 
over time, it could further be positively or negatively modulated though variations in 
the underlying wound matrix (e.g. via the omission of fibroblast or the addition of 
EGF). Furthermore, the model was used to recapitulate a TOC-typical “constitutive 
wound healing” phenotype and alleviate it subsequently via RNA interference for 
iRHOM2. 
 
Based on the presence of a functional permeability barrier, the normal-phenotype 
model was then used for the assessment of topically applied fluorescent 
nanopolymers. Subsequently to verifying a typical internalisation pattern and lack of 
overly cytotoxic effect on monolayer keratinocytes, negatively charged polymers 
were applied on top of explant skin and fully stratified organotypics in order to test 
for permeation across the uppermost layer and into the epidermis. After displaying 
a negligible penetrance of the polymers by themselves, they were applied in 
conjunction with penetration enhancers DMSO and BA, resulting in very similar 
enhancer-dependent changes for the epidermal localisation of the polymers on skin 
and organotypics. With the suitability of the model therefore being demonstrated it 
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was then taken one step further towards a relevant application by successfully trying 
to detect and quantify the delivery and release of FFA inside the tissue. Subsequently, 
further work could be undertaken by employing additional analysis methods (e.g. 
Franz cell diffusion chamber) or widening the application of the model to the 
assessment of other carrier systems.  
 
4.2. Limitations of the Organotypic Model 
 
In the course of establishing the culture model and its several applications, various 
shortcomings and limitations became apparent. While (minor) technical issues, such 
as the necessary analysis of transdermal polymer penetrance via Franz cells, the 
expansion of the wound model through additional components or the optimisation 
of compound applications, are comparatively easy to be addressed, the problematic 
of the immortalised cell lines is more elaborate. The application of immortalised 
patient-derived cell lines has undisputable advantages when it comes to the virtually 
unlimited availability of rare disease-specific material and the modelling of more 
complex and/or dominant gain-of-function mutations (Thomas et al. 2009; Blaydon 
et al. 2013; Brooke et al. 2014). But the tendency of HPV16 E6/7-immortalised cell 
lines to present hyperproliferative and even premalignant characteristics (especially 
in 3D skin equivalents) is well documented (Blanton et al. 1991; Delvenne et al. 2001; 
Pickard et al. 2015; Srivastava et al. 2015) and also apparent in the context of this 
project. As a result, skin equivalents show a comparatively high degree of variability 
(in between different cell lines of the same origin as well as in between batches of 
the same cell line) and a general hyperproliferation / invasion phenotype which 
potentially poses a problem in the modelling of hyperproliferative, inflammatory 
diseases. 
 
4.3. Potential Improvements for the Organotypic Model 
 
A straightforward solution for future applications would be the switch to a more 
preferable protocol for the generation of patient-derived cells. Different 
immortalisation methods have been shown to result in cell lines more suitable for 
complex modelling: hTERT-based immortalised cells have already been used in the 
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setup of relatively healthy skin equivalents (Dickson et al. 2000; Man et al. 2007; 
Reijnders et al. 2015) and the manipulation of the Rho/ROCK signalling pathway has 
recently emerged as a promising alternative to classic immortalisation protocols 
(McMullan et al. 2003). Using the specific ROCK inhibitor Y-27632 on primary 
keratinocytes results in a reversible transition into an effectively immortalised state 
with greatly increased proliferative capacity, while forgoing the introduction of 
exogenous genes (Chapman et al. 2010; Liu et al. 2012). Consequently, treated 
keratinocytes retain primary cell characteristics, revert back to normal senescence 
after treatment stop and are capable of forming very skin-like equivalents (van den 
Bogaard et al. 2012; Chapman et al. 2014). Alternatively, the induced pluripotency of 
patient-derived primary cells and subsequent reprogramming into keratinocyte 
suitable for high-quality skin equivalents is a well-established method (Itoh et al. 
2011; Petrova et al. 2014; Umegaki-arao et al. 2014). Another distinct advantage 
would hereby be the possibility of differentiating one iPSC line into different cell 
types and create complex tissue models from the same (mutated) genetic source, 
e.g. a dermal-epidermal model for dystrophic epidermolysis bullosa with fibroblast 
and keratinocytes being based on the same patient-derived iPSC culture (Itoh et al. 
2013). 
 
Since these approaches are not applicable to the existing (and irreplaceable) patient 
cell lines, another aim has to be the optimisation of the organotypic culture for 
already immortalised cell lines. One possible solution has already been implied in the 
course of this project: ADAM17-inhibitor TMI-005 has been demonstrated to reduce 
hyperproliferation and invasion in TOC and PC disease models. A preliminary attempt 
at translating these findings to a normal-phenotype skin equivalent resulted in the 
strikingly improved histology and expression of differentiation marker Involucrin in 




Variability in between cell lines immortalised with the same HPV-based protocol is 
another issue that became apparent in the early stage of this project. Since this 
variability cannot be excluded in the context of disease and control cell lines either 
and would potentially dampen disease-related differences (especially in regard to 
hyperproliferation-associated features), certain adjustments would be 
advantageous. The CRISPR/Cas9 system can be used to either introduce specific 
(disease-causing) mutations into healthy cells or perform genomic correction on 
disease cell lines (Li et al. 2016; Paquet et al. 2016), thereby providing the perfect 
tool to generate isogenic control-disease cell line pairs derived from a single 
immortalised cell line (Kim et al. 2014; Marthaler et al. 2016) and disregard the 










Figure 54: Effect of TMI-005 on HaCaT organotypics 
After culturing HaCaT organotypics for 10 days with the ADAM17 inhibitor TMI-005 (or DMSO for the 
control), striking differences in regard to histology and differentiation can be seen. The epidermal 
portion is less hyperproliferative and disordered but more stratified instead; suprabasal expression 
of differentiation marker Involucrin is concomitantly upregulated.  
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In addition to the variability in between cell lines, the inter-batch variability for each 
individual cell line in the context of complex organotypic culture systems has to be 
taken into consideration when interpreting results derived in this context. Therefore, 
thorough repetition for certain experiments would have to be undertaken in order 






Even though the established model system and applications are still in need of 
further optimisation (some of which is already in progress) and preliminary results 
have to be repeated and confirmed, it was so far possible to model several 
inflammatory disease phenotypes to some degree, recreate dermal wound healing 
features in vitro and use a functional epidermal barrier function in the organotypic 
to assess the application novel drug delivery systems. 
Consequently, the potential to advance this proof-of-principle project into a relevant 
tool for the investigation of cutaneous disease / wound models and possible 
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